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ABSTRACT 
Background 
At least 40 - 80% of all cancer patients develop some degree of clinical 
malnutrition and cachexia. The complex and multi-factorial nature of cancer 
cachexia and the inability of conventional nutrition intervention to reverse or 
attenuate the effects of this syndrome have driven investigators to consider 
new therapies and approaches to manage the syndrome of cancer cachexia 
including eicosapentaenoic acid (EPA), an n-3 fatty acid of fish oil origin.  
 
Objectives 
The aim of this study was to review Phase I, Phase II and Phase III (RCT) 
trials investigating the safety and efficacy of n-3 supplementation in the 
treatment of cancer cachexia in adult patients with unresectable solid 
tumours, with special reference to weight loss, body composition, appetite, 
dietary intake, energy expenditure, functional status, acute phase response 
and quality of life. Adverse effects associated with EPA supplementation were 
also reviewed. 
 
Methodology and data collection 
The major databases were systematically searched for studies that met the 
inclusion criteria using a structured keyword search strategy or various 
combinations of these keywords.  Relevancy of studies was assessed by two 
independent reviewers according to pre-determined inclusion and exclusion 
criteria.  Quality was assessed by two independent reviewers using the Jadad 
scale. Data extraction was performed by the principal reviewer and one of the 
independent reviewers, and investigators of the included studies were 
contacted where further information was required.  Meta-analysis was not 
appropriate due to heterogeneity of the data.  However, where possible, the 
paired t-test was used for analysis of the data. Descriptive or non-quantitative 
analysis of the tabulated data provided a summary of the characteristics of the 
included studies enabling comparisons to be made between interventions and 
outcomes within the specified population.  
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Results 
The search resulted in a total of 1408 citations, of which only 16 studies met 
the inclusion and exclusion criteria.  Of these, only 4 studies were of a good 
quality.  Although the reported data was incomplete and variable, the 
combined analyses suggested that the effect of EPA supplementation on 
weight, fat mass, dietary intake, energy expenditure, and acute phase 
response was not significant. Interestingly there appeared to be a significant 
increase increased or decreased?  in lean body mass (p<0.05). There was 
little or no data to draw any conclusions regarding the effect of 
supplementation on appetite and quality of life. 
 
Conclusion 
Despite several limitations in this review, the data collected and analysed are 
suggestive of the beneficial effects of EPA supplementation, but there remains 
a significant lack of substantial evidence and conclusive statistical analysis to 
confirm that EPA supplementation is a safe and effective method of 
intervention in the management of patients with cancer cachexia.  
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OPSOMMING 
Agtergrond 
Ten minste 40 – 80% van alle kanker pasiënte ontwikkel `n mate van kliniese 
wanvoeding en kanker kageksie. Die komplekse en multifaktoriale aard van 
kanker kageksie en die onvermoë van konvensionele voedingintervensies om 
die effek van die sindroom om te keer of te vertraag, het navorsers 
aangespoor om nuwe behandelings en benaderings te oorweeg vir die 
behandeling van kanker kageksie. Een van diė benaderings sluit in 
eikosapentanoësuur (EPS), `n n-3 vetsuur afkomstig van vis olie.  
Doel van studie 
Die doel van die studie was ’n oorsig van Fase I,  II en III studies om die 
veiligheid en effektiwiteit van n-3 supplementasie in die behandeling van 
kanker kageksie in volwasse pasiënte met onverwyderbare, soliede gewasse 
te bepaal, met spesiale verwysing na gewigsverlies, liggaamsamestelling, 
eetlus, dieetinname, energieverbruik, funksionele toestand, akute fase 
respons en lewenskwaliteit. Newe-effekte geassosieer met EPS 
supplementasie is ook ondersoek.  
Metodiek en data versameling  
Die belangrikste databasisse is sistematies  nagegaan vir studies volgens 
spesifieke insluitings kriteria deur van ‘n gestruktureerde soektog volgens 
sleutelwoorde, of deur middel van ‘n kombinasie van diė sleutelwoorde. Die 
toepaslikheid van studies is bepaal deur twee onafhanklike nasieners volgens 
voorafbepaalde insluitings en uitsluitings kriteria. Kwaliteit is met behulp van 
die Jadad skaal deur die twee onafhanklike nasieners bepaal . Die hoof 
nasiener en een van die onafhanklike nasieners  was verantwoordelik vir data 
ekstrahering.  Indien nodig, is die navorsers van die studies wat ingesluit was 
gekontak vir addisionele inligting. As gevolg van die heterogene aard van die 
studies was meta-analise nie moontlik nie.  Waar moontlik is die gepaarde t-
toets vir analise van die data gebruik. Beskrywende of nie-kwantitatiewe 
analise van die getabuleerde data het `n opsomming van die eienskappe van 
die ingeslote studies verskaf. Dit het toegelaat dat daar vergelykings gemaak 
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kon word tussen die intervensie en die uitkomste, binne die spesifieke 
populasie groep. 
Resultate 
Die soektog het 1408 studies geϊdentifiseer waarvan net 16 aan die insluitings 
en uitsluitings kriteria voldoen het. Slegs 4 van hierdie studies was egter van 
goeie kwaliteit. Alhoewel die gerapporteerde data onvolledig en uiteenlopend 
was, het die gekombineerde analise daarop gedui dat die effek van EPS 
supplementasie op gewig, vetmassa, dieet inname, energie verbruik, 
funksionele toestand en akute fase respons, nie beduidend is nie. ’n 
Interessante waarneming was dat daar `n beduidende verhoging was in maer 
liggaamsgewig na supplementasie (p<0.05). Daar was egter nie voldoende 
data om enige gevolgtrekkings te maak oor die effek van EPS supplementasie 
op eetlus of lewenskwaliteit nie. 
Gevolgtrekking  
Ten spyte van verskeie beperkings van hierdie oorsig, is die data wat 
ingesamel en geanaliseer was suggestief van ’n moontlike voordelige effek 
van EPS supplementasie. Daar is egter nog `n groot tekort aan substansiële 
bewyse en konkrete statistiese data om te bewys dat EPS supplementasie `n 
veilige en effektiewe metode van intervensie is in die behandeling van 
pasiënte met kanker kageksie. 
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1.1 INTRODUCTION 
Nutrition plays a significant role throughout the clinical course of the cancer 
disease process, with at least 40 - 80% of all cancer patients developing some 
degree of clinical malnutrition5. The association between malnutrition and 
weight loss and the increased risk of dying in patients with cancer has been a 
well established observation over the last 60 years. It is, however, only more 
recently that the role and challenge of nutrition intervention in this process of 
malnutrition has been investigated. In general terms, simple provision of 
nutrients does not help overcome the metabolic impact of malignancy6.  
 
At least 50% of patients with cancer lose weight prior to their diagnosis. 
Following the results of an earlier study, it has become a well-documented 
and accepted concept that poor performance status and weight loss of more 
than 10 % is associated with a poor response to treatment and shortened 
survival7. This study also established that the occurrence of weight loss 
differed with the type of malignancy. Certain subtypes of lymphomas, 
sarcomas, leukaemia and breast cancer are associated with a low incidence 
of weight loss, with only 30-40% of these patients losing weight, whereas a 
weight loss of 48 – 61% is documented with other subtypes of lymphoma, 
colon, prostrate and lung cancer. The group of patients known to have the 
highest incidence of weight loss are those with pancreatic and gastric cancer. 
At least 83 –87% of such patients will lose weight, a third of whom will lose 
more than 10% of their body weight7, 8. Furthermore, Dewys et al 7 have 
shown that survival time within each tumour type was influenced by the 
percentage of weight loss that occurs. A 30 % loss of body weight is 
frequently fatal. Nevertheless, a few patients have been able to survive 
despite a loss of up to 50% of their body weight7, 9. 
 
The pattern of weight loss seen in cancer patients is very different from the 
pattern seen during simple starvation, and forms part of a syndrome known as 
cachexia. In addition to the weight loss, cancer cachexia is characterised by 
anorexia, taste changes, early satiety and weakness. Starvation primarily 
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produces losses of fat but also of muscle and visceral protein, while cancer 
patients may lose up to 75% of muscle protein and up to 80% fat with 
preservation of visceral protein. It therefore appears that there are different 
mechanisms inducing weight loss in patients with cancer compared with those 
suffering starvation10, 11.  It is these differences that complicate the nutritional 
management of a cancer patient. 
 
1.1.1 Impact of cancer cachexia 
Unintentional weight loss in patients with cancer is merely one of the clinical 
features of a syndrome known as cancer cachexia (CC), which combines 
physiologic, metabolic and psychological factors. This reflects the 
multifactorial nature of the syndrome, which ultimately leads to a reduction in 
food intake, an increase in energy expenditure, or a combination of the two. 
Although there are no strict criteria for the specific diagnosis of CC, clinical 
manifestations include progressive involuntary weight loss and wasting, 
anaemia, anorexia, fatigue, hypoalbuminaemia, impaired immune function 
and poor performance status, all of which have a profound effect on the 
progression of the disease and have an overall effect in reducing the quality 
and possibly the quantity of life. 
 
CC can appear at any stage of the disease process and is present in at least 
50-80% of patients with malignancies. Over 20% of cancer related deaths are 
as a result of malnutrition and host tissue wasting6, 8, 11-13.  
 
1.1.2 Clinical Manifestations 
1.1.2.1 Anorexia  
Anorexia is a prominent component of cancer cachexia. It is the most 
common and clinically significant symptom and is characterised by a 
spontaneous decrease in dietary intake and adversely influences nutritional 
status14. Anorexia can consist of appetite loss and / or satiety as well as 
altered food preferences15. The frequency of anorexia in cancer can vary from 
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15-40% at presentation and up to 80% in patients with advanced cancer. 
Pain, mechanical obstruction of the gastrointestinal tract and various side 
effects of chemotherapy are some of the causes of the anorexia. However, 
the frequent absence of these causes has led to speculation that there may 
be other factors, either produced by the tumour or by the host in response to 
the tumour, that contribute to the anorexia. Further research has shown that 
leptin, a molecule secreted by adipose tissue, can influence food intake and 
energy expenditure and thus contribute to the anorexia seen in patients with 
cancer. One of the important aspects of the anorexia is its impact on a 
patient’s quality of life6, 12, 13. 
 
1.1.2.2 Weight loss 
Weight loss is a major prognostic indicator of poor survival and also 
contributes to a poor response to therapy. The loss in weight may occur as a 
result of poor dietary intake, the position of the tumour in the gastrointestinal 
tract, side effects of radiotherapy and/or chemotherapy, pain and emotional 
distress. The weight loss impacts a patient’s performance status which in turn 
will have a negative effect on quality of life13. 
 
1.1.2.3 Gastrointestinal Complications 
A variety of symptoms such as early satiety, taste changes, xerostomia, 
nausea, vomiting, diarrhoea and constipation can result from the tumour or be 
a consequence of treatment. Furthermore, direct involvement of the tumour 
can alter the digestion and absorption of nutrients which may directly or 
indirectly influence nutritional status. 
 
1.1.2.4 Quality of life 
The clinical manifestations of CC all have a negative effect on nutritional 
status and are closely associated with quality of life which in turn will have a 
direct impact on a patient’s ability to maintain simple activities of daily living, 
result in changes in body image and contribute to depression and interfere 
Stellenbosch University http://scholar.sun.ac.za
 5
with family and social relationships. It is this significant impact on quality of life 
that very often initiates the process of investigations and consequent 
diagnosis of cancer13, 16, 17. 
 
1.1.3 Mechanisms and mediators of cancer cachexia 
The altered dietary intake resulting from many of the factors already 
discussed, cannot adequately explain the inability of patients with cancer to 
maintain or gain weight. Other possibilities thought to be playing a role include 
hypermetabolism and altered metabolism of carbohydrate, protein, and fat. 
Furthermore, certain mediators have also been implicated in the development 
of cancer cachexia (Figure1.1)13. 
 
Hypermetabolism describes the raised resting energy expenditure, which is a 
feature in patients with cachexia but not in starvation18. Approximately 60% of 
patients with cancer have abnormal resting energy expenditure (REE) with 
studies showing that the REE can range from less than 60% to more than 
150% of predicted values, with approximately 35% being hypometabolic and 
25% being hypermetabolic.  
 
A recent study has confirmed that REE is raised in patients with pancreatic 
cancer which may play a role in accelerating the wasting and further increase 
the energy deficit already present in these patients19. 
 
Studies performed in animals have also shown that energy expenditure 
changes with disease progression. Initially, there is a period of 
hypermetabolism which then changes to a relatively normometabolic phase to 
a preterminal hypometabolic phase. Although such measurements have not 
been investigated in humans, this pattern could account for the some of the 
observed variation in energy expenditure. In addition to this, the tumour type 
plays an important role in determining energy expenditure. Although there 
may be changes in REE, total energy expenditure may be unchanged due to 
a reduced level of physical activity, thus maintaining the overall energy 
balance13, 20-22. 
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A variety of changes in nutrient metabolism in patients with cancer have been 
described, which emphasize that CC is more than a failure to meet nutritional 
requirements with dietary intake6, 21. The changes in carbohydrate metabolism 
are characterised by a relative glucose intolerance and insulin resistance. 
There is an increased glucose production of up to 40% and a 2-5 fold increase 
in glucose recycling through the Cori cycle in response to tumour production 
of lactic acid. It appears that disease progression makes these changes more 
pronounced, and it has been suggested that the energy cost of these changes 
is approximately 260 kcal/d6, 10, 20, 21. 
 
The significant depletion of fat stores is one of the most obvious and 
characteristic features of CC and accounts for the wasted appearance of 
many patients with cancer. This depletion is associated with elevated fat 
oxidation rates; however, the abnormalities in fat metabolism can be attributed 
to reduced lipogenesis as opposed to increased lipolysis rates. This may be 
secondary to decreased levels of lipoprotein lipase (LPL), which can also 
result in a type IV hyperlipidaemia. The raised level of circulating lipids is 
thought to facilitate the provision of energy for the host, but as with 
carbohydrates, these lipids may be providing the tumour with additional 
nutrients to meet its metabolic requirements6, 10, 21. 
 
Similar to the loss of fat stores, muscle wasting is another prominent feature 
of CC and is a major factor responsible for reduced survival time in cancer 
patients. However, despite an increased whole-body protein turnover, which 
appears to increase with disease progression, protein breakdown rates in 
cancer patients have not been found to be very different from controls. Instead 
there appears to be a decrease in protein synthesis producing a net protein 
breakdown.  There also appears to be reprioritisation of hepatic protein 
synthesis, also referred to as the acute phase response, which has been 
associated with the acceleration of weight loss seen in patients with cancers 
such as pancreas, lung and melanoma. It is also possible that the acute 
phase response contributes to shortened survival by accelerating the 
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development of muscle wasting as a result of greater demand for amino acids 
to support increased hepatic export protein synthesis6, 10, 18, 20, 21, 23. 
Although it has been established that a tumour could be regarded as a new 
organ, which contributes to an increased demand for nutrients and to weight 
loss if these requirements are not met, the presence and severity of the 
cachexia correlates poorly with the size of tumour and cannot provide an 
explanation for the early clinical manifestations such as a change in appetite 
and altered nutrient metabolism. It is therefore thought that the metabolic 
changes could be the result of mediators produced by the tumour or the host’s 
response to the tumour. Such mediators include neurotransmitters, cytokines, 
neuroendocrine hormones and tumour-specific products10, 20, 21. 
 
Proinflammatory cytokines such as tumour necrosis factor (TNF), interleukin-1 
(IL-1), interleukin-6 (IL-6), interferon gamma (INF-γ) and ciliary neurotrophic 
factor (CNTF) have been implicated in the development of CC. Administration 
of these cytokines in animals produces anorexia, weight loss, an acute phase 
protein response, protein and fat breakdown, raised levels of cortisol and 
glucagon, decreased insulin levels, insulin resistance, anaemia, fever and 
elevated energy expenditure. Identifying raised levels of these cytokines and 
the effects thereof in humans has been more difficult; however, the cachectic 
effects are thought to be the action of a combination of pro-inflammatory 
cytokines as opposed to individual cytokines acting alone 20, 21, 24. 
 
Changes in hormone regulation and sensitivity, independent of the cytokine 
network, may also play a role in the pathogenesis of CC. The administration of 
the hormones cortisol, glucagon and adrenaline in humans produces features 
of CC. Furthermore, raised levels of cortisol and glucagon have been 
observed in people with cancer, which is thought to amplify the acute phase 
response. The raised levels of cortisol is also thought to alter the 
cortisol:insulin ratio which in turn may contribute to the catabolism of 
peripheral tissues. Therapeutic manipulation of these hormonal changes are, 
however, difficult to achieve and may interfere with what is thought to be an 
adaptive response6, 10, 21. 
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The inability of cytokines to independently induce cachexia in an experimental 
model has led to the identification of additional potential mediators, which are 
thought to be tumour-derived. Proteolysis-inducing factor (PIF) and lipid 
mobilizing factor (LMF) have been identified in the urine and tumour cells of 
weight-losing cancer patients but not in weight stable patients. PIF is therefore 
thought to play a role in protein breakdown and non-fat weight loss whereas 
the LMF can account for the loss of body fat and possibly contribute to the 
increase in energy expenditure18, 20, 21, 24. 
 
 Gaining greater understanding of the different mediators and their roles in the 
development of CC in humans may provide the opportunity and potential to 
better manage and improve the quality of life of patients with cancer cachexia. 
 
Figure 1.1 Metabolic effects of tumours25 
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1.1.4 Intervention and management of cancer cachexia 
Managing cancer cachexia is challenging. Curing the cancer would be the 
ideal intervention; unfortunately this remains a rare achievement in adults with 
solid tumours. The alternative approach is therefore to consider the role of 
nutrition intervention in order to  increase nutritional intake 13, 20, 24. 
 
The goal of nutrition support in the cancer patient should be to minimise 
weight loss, prevent nutrient deficiencies, support immune function, aid tissue 
repair and wound healing and ultimately contribute towards maintaining and / 
or improving quality of life26. 
 
Options to achieve such goals can vary from dietary counselling and oral 
supplementation to the use of enteral and parenteral nutrition. It was hoped 
that these options would be adequate to help overcome anorexia and alleviate 
malnutrition. Unfortunately, such interventions have repeatedly shown that 
despite an increase in total energy intake, there is little change in terms of 
weight, anthropometric measurements, response rate, survival or quality of 
life. Parenteral nutrition has also been associated with its own complications, 
difficulties with long-term use thereof, and it has failed to show any significant 
survival benefit or decrease in chemotherapy-induced toxicity. Although there 
is a lack of clinical evidence, there still remains a certain amount of 
controversy regarding the effect that nutrition support has on tumour growth 
and development13, 18, 21, 27. 
 
Despite the inability of nutrition support to influence or reverse the effects of 
cancer cachexia, it remains an important means of intervention for a certain 
subset of patients. More careful consideration regarding appropriate patient 
selection and route of administration needs to be given to ensure that the 
intervention is going to be effective. 
 
The limitations of conventional nutrition support to effectively manage cancer 
cachexia have led to the use of a number of pharmacologic agents to try to 
modulate the underlying metabolic problems, thus improving the effectiveness 
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of the nutrition intervention, and to treat or provide symptomatic relief for 
patients with CC6, 21. 
 
The most widely used pharmacologic agents for cancer cachexia are 
corticosteroids and progestational agents. Corticosteroids are frequently used 
for their appetite stimulating effects and to increase well being. They have a 
significant anti-nausea effect and help control asthenia and pain. The effects 
are, however, short-lived, and any change in weight is usually an 
accumulation of fluid as opposed to body weight gain. In addition to this, the 
use of corticosteroids is associated with other adverse effects such as 
oedema, muscle weakness, dysphoria, hypokaleamia, hyperglycaemia and 
immune suppression, that limit their use to the preterminal phase of disease 
(Table 1.1). Similarly the use of anabolic steroids has also been suggested as 
an appetite stimulant but the associated adverse effects also limit their use13, 
18, 20, 21. 
 
Progestational agents such as megesterol acetate (MA) and 
medroxyprogesterone acetate (MPA) were initially used in the treatment of 
metastatic breast cancer. The unwanted weight gain and appetite 
enhancement seen in these patients using these agents led to them being 
used in patients with CC (Table1.1). Further trials using these agents have 
found that they are well tolerated at high doses and have few adverse effects. 
The mechanism of action remains unknown but following the finding that 
serum levels of cytokines decreased with the use of MA and MPA, it has been 
suggested they have steroid-like effects. Unfortunately, despite the appetite 
enhancement, the weight gain seen with MA is adipose and not lean body 
mass (LBM) and the use of MPA failed to show an improvement in weight, 
performance status, energy or mood. Of more concern is that a recent trial 
with MA showed that patients had a poor response to chemotherapy and a 
trend to poorer survival13, 18, 21. 
 
Prokinetic agents such as metoclopramide may be beneficial in the relief of 
nausea, anorexia and early satiety associated with gastric stasis (Table 1.1). 
The roles of other prokinetic agents still require further investigation13, 18. 
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Hydrazine sulphate, tetrahydrocannabinol derivatives, cyproheptadine, 
pentoxifylline are further examples of other agents that have been used in the 
management of CC. The greatest impact is on appetite and nausea, but 
unfortunately they have failed to prevent further weight loss, and there remain 
uncertainties with regards to the safe use of some of them6, 13, 18, 21. 
 
There are other drugs now being considered for the management of CC. 
Limited evidence is available regarding their potential use.   However, larger 
randomized studies are needed to assess the efficacy of these new options. 
These include melatonin, thalidomide, β2-agonists and NSAIDs18. 
 
A further future consideration with the management of CC is the role of 
combination therapy. In other words, maybe the combination of diet 
intervention with one or more of the pharmacological agents will be more 
effective than the current approach. Such options will, however, need to be 
investigated. Nevertheless, emerging evidence on the combination of MA 
(progestational agent) and Ibuprofen (NSAIDs); suggests that this 
combination may stabilize quality of life and weight in advanced 
gastrointestinal cancer20, 21.  
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Table 1.1 The main pharmacological agents used in the management of cancer cachexia6, 13 
CLASSIFICATION  NAME OF 
AGENT 
POTENTIAL BENEFITS 
IN MANAGING 
CANCER CACHEXIA 
REASONS FOR LIMITED USE 
IN PATIENTS WITH CANCER  
Corticosteroids Appetite stimulant 
Increased sense of well 
being 
Anti-nausea 
Oedema 
Muscle weakness 
Dysphoria 
Hypokalaemia 
Hyperglycaemia 
Immunosuppressive 
Steroids 
Anabolic steroids Appetite stimulant  
Megesterol 
Acetate 
Appetite stimulant Weight gain mainly adipose and 
not LBM 
Possible poorer response to 
chemotherapy  
Possible trend to poorer survival  
Progestational 
Agents 
Medroxy-
progesterone 
Appetite stimulant No improvement in weight, 
performance status or mood 
Prokinetics Metoclopramide Anti-nausea 
Anti-anorexic 
Increases gastric motility 
 
 
1.2 n-3 Fatty acids and cancer cachexia 
In evaluating new therapies to treat cancer cachexia, the role of omega-3 (n-
3) fatty acids in cancer has only recently been considered. Initial interest in n-
3 fatty acids stems from the association of the high n-3 diet of Greenland 
Eskimos and their low incidence of cancer and coronary heart disease.  
 
Omega-3 fatty acids are long-chain, polyunsaturated fatty acids which cannot 
be synthesised by the human body, they are thus an essential part of the 
diet28. They are derived from plant and  marine origin and are found in the diet 
as a component of oily fish, flaxseed, hemp, canola and walnut oils. The n-3 
fatty acids are involved in the synthesis of eicosanoids (prostaglandins, 
leukotrienes, and thromboxanes) and in membrane, receptor and enzyme 
function. The major metabolically active n-3 fatty acid component of oily fish is 
eicosapentanoic acid (EPA). Similarly, the metabolically active n-3 fatty acid 
component of plant sources is alpha linoleic acid which is metabolised in the 
liver to EPA28.  
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Omega-3 fatty acids and its role and actions in cancer cachexia are multi-
faceted. It would appear that EPA is able to affect the production and end 
organ effects of a number of potential mediators of cachexia20, 29-31. 
 
 The eicosanoids and prostanoids, such as PGE2, produced by the malignant 
tumour are thought to encourage angiogenesis and metastasis. However, 
results from several animal studies are indicating that by enriching the diet 
with fish oil, the EPA is able to alter the metabolism and production of the 
prostaglandins and leukotrienes and thus play a role in growth of tumour cells. 
Although complete tumour inhibition has not been observed, there is certainly 
tumour cell growth retardation, which warrants further research. Furthermore, 
a decrease in the formation of the immunosuppressive PGE2 is also 
associated with a probable improvement in the host’s immunologic defence 
against cancer29, 30, 32, 33 . 
 
Further experimental studies have shown that the administration of EPA 
reduces the production of the cytokines IL-6, IL-1 and TNF in healthy subjects, 
and TNF and IL-6 in patients with pancreatic cancer, and the effect appears to 
be maintained for weeks following the supplementation. The mechanism of 
action occurs through the substitution of EPA for arachidonic acid (AA), which 
results in decreased cytokine and prostanoid production20, 30, 31, 33. 
 
Animal studies have also been able to show that EPA can inhibit fat and 
protein breakdown, and this is possibly attributable to EPA’s inhibition of the 
end-organ effects of the tumour-derived lipolytic and proteolytic factors20, 29, 31, 
34.  A clinical trial investigating the effects of EPA supplementation on the 
mediators of cachexia found that three weeks of supplementation produced a 
significant decrease in PIF levels excreted in the urine34. 
 
Completed clinical trials using EPA supplements have found that it promotes 
weight maintenance, improves food intake, inhibits tumour growth and may 
improve survival. It therefore appears that EPA has the potential to be an 
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effective non-toxic, anti-cachectic and anti-inflammatory agent. To enhance 
these effects, trials using an n-3 enriched nutritional supplement have been 
and continue to be carried out. The motivation to use such an enriched 
supplement is to modulate the process of cachexia with the EPA as well as 
supply additional energy and protein to encourage an improvement in weight 
and lean body mass and thus ultimately contribute to improved functional 
ability20, 30, 32, 35. 
 
1.3 Motivation of the study  
The purpose of this study was to systematically review the available evidence 
on the safety and efficacy of EPA supplementation derived either from an n-3 
enriched nutritional supplement or as fish oil capsules in patients with 
pancreatic malignancy, and to search for evidence of trials that have 
incorporated cancers other than pancreatic cancer.  
 
Although the results are favourable and appear to be associated with few 
adverse effects, there is little data available with regards to achieving similar 
benefits with n-3 enriched nutritional supplements used in other cancers 
associated with cancer cachexia. Similarly there is little evidence considering 
the impact that the use of n-3 enriched nutritional supplements will have on a 
patient’s quality of life. 
 
The findings will facilitate the implementation of guidelines for medical 
professionals with regards to the use of n-3 enriched nutritional supplements 
in cancer. 
Stellenbosch University http://scholar.sun.ac.za
 15
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2: METHODOLOGY 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University http://scholar.sun.ac.za
 16
 
2.1 AIM AND OBJECTIVES OF STUDY 
 
2.1.1 Aim  
The initial aim was to perform a systematic review of randomised controlled 
trials regarding the safety and efficacy of n-3 enriched nutritional supplements 
in the treatment of cancer cachexia in adult patients with unresectable solid 
tumours.  
 
The search and selection of studies according to this criteria was, however, 
very disappointing because there were far fewer studies on the topic than 
anticipated;   the scope of the study was therefore extended to include Phase 
I, Phase II and Phase III (RCT) trials investigating the safety and efficacy of n-
3 supplements and n-3 enriched nutritional supplements in the treatment of 
cancer cachexia in adult patients with unresectable solid tumours. The latter 
criteria form the basis of this study. 
 
2.1 .2 Objectives  
The primary objectives of the review were as follows: 
• To establish if the use of an eicosapentaenoic acid (EPA) supplement 
can attenuate or reverse the weight loss experienced in patients with 
cancer cachexia 
• To establish the effect that the use of an EPA supplement will have on 
body composition in patients with cancer cachexia 
• To establish if appetite and dietary intake in patients with cancer 
cachexia is altered following the use of an EPA supplement 
• To establish if the use of an EPA supplement can influence energy 
expenditure in patients with cancer cachexia 
• To establish if the use of an EPA supplement can improve functional 
status in patients with cancer cachexia  
• To establish the influence EPA supplements may have on the acute 
phase response in patients with cancer cachexia  
• To establish if the use of EPA supplements can improve the quality of 
life of patients with cancer cachexia. Quality of life is usually assessed 
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by means of a questionnaire considering a combination of mental, 
emotional and physical aspects. 
• To define any adverse effects associated with the use of EPA 
supplements 
 
The secondary objective of the study is as follows: 
• To determine if trials have considered the use of EPA supplements in 
cancers other than pancreatic cancer (majority of the studies used 
patients with pancreatic cancer) 
 
2.2 STUDY PLAN 
2.2.1 Study Design 
A systematic review of Phase I, Phase II and Randomised controlled trials. 
 
2.2.2 Scope of the study 
The studies that were reviewed related to adult patients with an unequivocal 
diagnosis of cancer with symptoms of cancer cachexia, who received EPA 
supplementation either in the form of a fish oil capsule or as an enriched 
nutritional supplement.  
 
2.3  LITERATURE SEARCH 
A search of several sources of evidence was completed during May and June 
2004. To establish the extent to which this topic has been researched, the 
search period was initially not restricted; however, for final inclusion in the 
review, studies must have been completed in the last ten years to ensure that 
this study’s findings are based on the most recent evidence available. Search 
results were limited to English. Although this initial search used very broad 
search criteria (Table 2.1) and was not very specific, it did allow for the 
maximum number of potentially relevant studies to be identified. Once these 
were identified, stricter inclusion and exclusion criteria were applied to these 
studies for final inclusion (Table 2.7).  
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Table 2.1 Initial selection criteria used to identify potentially relevant studies 
SELECTION CRITERIA KEYWORDS AND RESTRICTIONS USED IN 
SEARCHES 
Study Population - Not restricted to adults at this stage 
- Cancer and related terms 
Intervention - Nutritional supplements 
- Fish oil supplements 
- n-3 fatty acids and related terms 
Study Design Not restricted at this stage 
Language Restricted to English 
Search Period Not restricted at this stage 
 
2.3.1 Electronic Bibliographic Databases 
The major databases, MEDLINE, CINAHL, EMBASE, Ovid, The Cochrane 
Library, Zetoc and NHS CRD databases (DARE & NHS EED) were searched 
to identify potential relevant citations.  
 
The following search strategy was devised and entered into the databases 
that allowed a structured keyword search to be used: 
 
1. exp. Cancer / 
2. tumour.mp 
3. 1 or 2 
4. exp.eicosapentaenoic acid / 
5. exp.fish oil / 
6. exp. Omega-3 fatty acids / 
7. nutritional supplement.mp 
8. (fish oil adj2 supplement).mp 
9. 4 or 5 or 6 or 7 or 8 
10.  3 and 9 
 
Various combinations of these keywords were used to search databases that 
did not allow for a structured keyword search to be used. A disadvantage of 
the unstructured keyword search was that it increased the likelihood of 
relevant information being overlooked. To minimise this effect, broader search 
terms were used. 
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On completion, this search produced 405 citations of which 85 were selected 
by the principal reviewer as potentially relevant citations (Table 2.2). They 
were selected according to the criteria specified in Table 2.1.  
 
Table 2.2 Summary of the electronic databases searched and number of potentially useful 
citations identified 
DATABASE PERIOD 
SEARCHED IN 
DATABASE 
TOTAL 
CITATIONS* 
POTENTIALLY 
USEFUL CITATIONS 
MEDLINE/EMBASE/CINAHL 1951-/1974-/1982-2004 140 41 
OVID 1950-2004 55 6 
ZETOC Not specified 188 35 
DARE/NHS EED Not specified 20 1 
COCHRANE LIBRARY Not specified 2 2 
Total  405 85 
*Totals have been corrected for duplicate citations 
 
2.3.2 Research Registers 
Local, national and specialist research registers were searched for data 
regarding recently completed and ongoing research. Various combinations of 
the keywords produced a total of 64 citations (Table 2.3). According to the 
specified selection criteria (Table 2.1), the principal reviewer selected 15 
potentially relevant citations.  
 
Table 2.3 Summary of the research registers searched and the number of potential citations 
identified 
RESEARCH REGISTER TOTAL CITATIONS* POTENTIALLY USEFUL 
CITATIONS 
NRR 15 13 
metaRegister of clinical trials 49 2 
UK CCCR 0 0 
NCI 0 0 
CORDIS 0 0 
Total 64 15 
*Totals have been corrected for duplicate citations 
 
 
2.3.3 Internet 
The Internet is another option to search for completed and ongoing research; 
it would however be an enormous task unless a structured approach is used. 
As per recommendation the following meta search engines were searched:2, 36   
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www.copernic.com 
www.dogpile.com 
www.omni.ac.uk 
www.mednets.com/ 
 
As with the databases and registers, the same combinations of keywords 
were entered into each search engine. The search produced a total of 929 
sites, many of which were the same. Unfortunately, combining the results from 
each search to produce a more accurate total number of citations found would 
have been too complex and time consuming. After duplicates were eliminated, 
the principal reviewer selected potential citations from each search according 
to the specified selection criteria (Table 2.1). The search on the internet 
produced 20 potential citations, of which the findings are summarised in Table 
2.4. 
 
Table 2.4 Summary of the internet search and number of potential citations identified 
META SEARCH ENGINE TOTAL CITATIONS POTENTIALLY USEFUL 
CITATIONS 
www.copernic.com 478 
www.dogpile.com 398 
20 
 
www.omni.ac.uk 42 0 
www.mednets.com/ 11 0 
Total 929 20 
 
2.3.4 Investigators and manufacturers 
 
Investigators who had completed trials on this topic were consulted via email 
to establish whether there was further information regarding ongoing research 
that could be considered for this review. The manufacturers of the n-3 
enriched nutritional supplement were approached for any literature that could 
contribute to the comprehensiveness of this literature search. 
 
The response received from investigators was varied. Prompt responses from 
some investigators facilitated the search process, but unfortunately, despite 
several attempts, some investigators failed to respond. Only 2 investigators 
were able to provide further information which facilitated the search. 
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2.3.5. Reference Lists, Conference Proceedings and Grey Literature 
To ensure that relevant studies were not overlooked in the electronic 
searching, the reference lists of primary studies and reviews were scanned 
manually to identify further studies which could be considered for the 
systematic review. Any other format, which might have not been indexed in 
the major databases, was searched for on SIGLE (System for Information on 
Grey Literature). Similarly, the following databases on conference 
proceedings were searched for information regarding ongoing research: ISTP 
(Index to Scientific and Technical Proceedings), Dissertation Abstracts, Index 
of Conference Proceedings, and Conference Papers Index (Table 2.5). 
 
Table 2.5 Summary of the search for grey literature  
DATABASE SEARCHED RESULTS 
Research findings register  None 
NHS Research and development health technology 
assessments 
None 
National Technical Information Service None 
SIGLE None 
 
2.4  INCLUSION AND EXCLUSION OF STUDIES 
Upon completion of the literature search, 96 potentially relevant studies had 
been identified. Animal studies, language, and studies on other topics were 
the main reasons for exclusion. 
The search strategy was more sensitive than specific, but this did ensure that 
more primary studies could be identified and used to review reference lists. 
Many of the studies considered to be relevant were review articles as 
opposed to clinical trials, but were included in this part of the search to 
facilitate the search of reference lists, thereby ensuring that no trials were 
overlooked. 
 
During July 2004 – August / September 2004 the full reference of the 96 
relevant studies were requested, of which only 76 were available for further 
review (Table 2.6)  
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Table 2.6 Initial exclusion of studies 
REASON FOR EXCLUSION NUMBER OF STUDIES EXCLUDED 
Failed requests 7 
Language 1 
Study not requested 1 
Current trial with no available results 2 
Completed trial with no available results yet 9* 
TOTAL EXCLUDED STUDIES 20 
* Although the initial search identified them as 9 individual trials, they are part of the same multicentre trial 
 
 
Table 2.7 Inclusion and exclusion criteria for the final selection of studies 
Inclusion Criteria Exclusion Criteria 
Adult patients with solid tumours Adult patients with other cancers           
(E.g. leukaemia) 
Patients receiving only EPA supplements or  EPA 
enriched nutritional supplements 
EPA supplements or EPA enriched nutritional 
supplement in combination with other nutritional 
supplements 
1 or more of the following outcomes 
- Attenuation or reversal of weight 
loss 
- Change in body composition 
- Change in energy expenditure 
- Change in appetite or dietary 
intake 
- Change in functional status 
- Alteration in tumour growth or 
acute phase response 
- Improvement of quality of life 
- Adverse affects associated with 
the EPA supplementation 
Outcomes not considered in the objectives 
Phase I, II, III (RCT) controlled trials Other study designs 
Studies completed between 1994-2004 Studies completed prior to 1994 
 
Two independent reviewers applied the inclusion and exclusion criteria to the 
76 studies and identified 16 studies that could be included in this study. A third 
reviewer was required to settle a disagreement regarding the inclusion of two 
of the studies, both of which were finally included (Figure 2.1). The reviewers 
that assisted in the selection process were both allied health professionals 
and despite their experience, neither was expert in this particular topic. The 
risk of selection bias was therefore minimised. 
 
There were a variety of reasons (Table 2.8) for studies being excluded. A 
more detailed list of the characteristics of excluded studies has been 
appended (Appendix 6.4) for reference purposes. 
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Table 2.8 Summary of the reasons which excluded studies after the final selection process 
REASON FOR EXCLUSION NUMBER EXCLUDED 
Animal studies 10 
Review articles 29 
Abstracts / Protocols 10 
Commentaries / Letters 5 
Not meeting inclusion criteria 5 
Other 1 
TOTAL NUMBER OF STUDIES EXCLUDED 60 
 
 
To maintain anonymity and reduce the risk of publication bias, all the studies 
were allocated a study identification number (Appendix 6.4-6.5). The included 
studies’ identification numbers (Appendix 6.5) were used throughout this study 
in the data extraction forms, tables and figures. The full references and their 
corresponding identification number are listed in the appendix. 
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Figure 2.1 Diagrammatic representation of the process followed in the selection of studies 
 
2.5 QUALITY ASSESSMENT OF INCLUDED STUDIES 
 
Randomised controlled trials are generally regarded as the best means of 
assessing medical interventions. However, variation in internal validity could 
influence the results of trials and thus influence the effect size of the review. 
As bias can affect internal validity,2 it is essential to utilise a means to assess 
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the quality of primary studies. To assess the quality of studies included in this 
study, a scale developed by Jadad et al 37 was used.  
 
This particular scale considers the four main sources of bias in trials, namely 
selection, performance, measurement and attrition bias, and has been 
selected for its simplicity and validity (Appendices 6.6- 6.7). An additional 
benefit of this scale is that reviewers do not need to be familiar with the topic 
or have research experience37.  
 
Using the quality assessment tool (Appendix 6.7), two independent reviewers 
scored each of the included studies. Table 2.9 and 2.10 summarises the 
scores and associated quality of these studies as well as differentiating 
between the quality of the different study designs. Appendix 6.8 provides a 
detailed description of each study’s quality assessment. 
 
The quality of the studies was incorporated in the analysis of data as a means 
of establishing the extent of heterogeneity and to assist decision-making 
regarding the suitability of the included studies for meta-analysis2.   
 
Table 2.9 Study quality and scores of included trials 
STUDY SCORE STUDY QUALITY NO. OF STUDIES (n) 
Less than 3 Poor 12 
3 and above Good 4 
n represents the number of studies 
 
 
Table 2.10 – Study quality according to study design 
STUDY QUALITY (n) TRIAL TYPE 
Good Poor 
Phase I 0 5 
Phase II 0 6 
Phase III (RCT) 4 1 
TOTAL  4 12 
n represents the number of studies 
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2.6 DATA EXTRACTION 
 
The principal reviewer collected the data. To ensure that the data collection 
was thorough and standardised, tables were designed for each of the 
outcomes being investigated (Appendices 6.9.1 – 6.9.11). 
 
One of the independent reviewers assisted with the data collection in 
situations where the required data was not clearly reported in the studies 
included in the review. To enable and ensure that the objectives of this review 
were met, investigators of the included studies were contacted for data that 
had been measured but not reported, and in some situations, for clarification 
on data that was reported. Unfortunately, there was a very poor response 
from the investigators who were contacted. Only one investigator provided the 
additional information that was requested.  
 
2.7 STATISTICAL ANALYSIS 
 
The Faculty of Health Science, University of Stellenbosch allocated a 
statistician to assist with the analysis of the data. 
 
Descriptive or non-quantitative analysis of the tabulated data provided a 
summary of the characteristics of the included studies enabling comparisons 
to be made between interventions and outcomes within the specified 
population. The descriptive analysis also provided the basis whereby a 
decision could be made as to the suitability and appropriateness of the data 
for quantitative analysis (meta-analysis). 
 
Ideally being able to perform a meta-analysis would have allowed a measure 
of effect of the intervention to be calculated between outcomes of the 
experimental group and the control group of individual studies. This would 
have enabled the direction and magnitude of the treatment effect to be 
determined. 
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The data that was collected was unfortunately too sparse and the different 
methods of intervention, trial designs and quality have made the data too 
heterogeneous to perform quantitative analysis. 
 
Although meta-analysis could not be performed and despite the data being 
inconsistent and incomplete, statistical analyses on the baseline and end of 
treatment data were performed using Excel and Statistica 7 data analysis 
programmes. Ordinarily this data should have been tested for normal 
distribution, but given the lack of adequate data, it was assumed that there 
was a normal distribution to allow the opportunity to calculate if there is a 
difference following the period supplementation with EPA. The paired t-test 
was used for this calculation. In situations where the data was not normally 
distributed, the Wilcoxon test was used instead of the paired t-test. Although 
this test was used and reported in the results section, it must be noted that the 
analyses only incorporated very small study numbers, which will have an 
influence on the strength of the results and should not be relied upon in the 
interpretation thereof. 
 
2.8 ETHICS CONSIDERATIONS 
The research protocol for the study was approved by the Ethics Committee, 
Faculty of Health Sciences, Tygerberg, University of Stellenbosch, South 
Africa (N04/03/051 Appendix 6.1). Approval was obtained to proceed with this 
review.  
 
 
 
 
Stellenbosch University http://scholar.sun.ac.za
 28
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 3: RESULTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University http://scholar.sun.ac.za
 29
3.1 CHARACTERISTICS OF STUDIES INCLUDED 
This study comprised of the evaluation of 16 studies. Eleven of the studies 
were Phase I and II trials and 5 were Phase III trials/ RCT.  Twelve of the 
studies were of poor quality (Table 2.10, Appendix 6.8).  
 
3.2 CHARACTERISTICS OF THE REVIEW POPULATION 
The studies included in this study engaged a total population of 640 patients 
at baseline, of whom the majority had been treated with EPA [Controls 
(n=227) versus Treated (n=413)]. There was a mean drop-out rate of 35% by 
the end of the treatment period, which reduced the treated population to a 
total of 269 patients [Control (n=160) versus Treated (n=269)] (Table 3.1).The 
drop-out rate of patients using capsules compared to an enriched nutritional 
supplement was 46% and 36% respectively (Table 3.2).  The treated 
population comprised 184 men and 147 women with a mean age of 62.2 
years; the median age was 63 years and the age range was 56 – 67 years. 
The median weight loss experienced among the patients at the pre-treatment 
stage was 16% (mean weight loss was 15.1%) over a median period of 6 
months  duration (mean 4.9 months) as opposed to the control patient group 
who lost a median of 11.8 – 14.6% (mean 12.3%) of their body weight over a 
period of 6 months duration (Table 3.1, Appendix 6.9.2). 
 
It must be noted that not all 16 studies provided complete details. The 
discrepancies that exist in the total number of patients are as a result of 
calculations being made in this study with the available reported data, which 
were not necessarily consistent or accurate. The means and medians were 
also only based on the number of studies that had adequate details.  
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Table 3.1 Summary of study population characteristics 
 * The number of studies providing details 
** 4 Studies did not specify details regarding withdrawals, therefore an assumption has been made that the sample 
size at the  
end was the same size as at baseline – this may not therefore be an accurate representation of the sample sizes at 
the end of treatment 
*** 3 studies did not specify the ratio of males to females and 1 study based their ratio on the number of people that 
completed the trial, compared to all the other studies that have based it on their baseline characteristics 
EPA – Eicosapentaenoic acid 
ENS – Enriched nutritional supplement 
 
Table 3.2 Summary of the % drop-out calculated according to the type of supplement that 
was used 
SUPPLEMENT USED POPULATION AT 
BASELINE (n) 
POPULATION AT END 
OF TRIAL (n) 
% DROP-OUT 
ENS 178 122 36% 
Capsules 235 147 46% 
Total 413 269 35% 
n - Represents the number of patients in the study population 
ENS – Enriched nutritional supplement 
 
The majority of the patients [Controls (n=142) versus Treated (n=271)] 
included in the studies had cancer of the pancreas.   Only 5 of the 16 trials 
included in this review considered other tumour sites. A total of 17 tumour 
sites were included in these studies (Table 3.3). Although the inclusion criteria 
specified that only studies with solid tumours were going to be included, there 
were three studies which included patients with solid tumours as well as other 
types of tumours. The total number of patients with tumours not classified as 
solid was 6 [Control (n=1) versus Treated (n=5), where n=number of patients], 
CONTROLLED STUDIES  
(n= 7) 
UNCONTROLLED STUDIES 
(n=9) 
TOTAL 
(n=16) 
POPULATION 
CHARACTERISTIC 
TREATED CONTROL TREATED TREATED 
ONLY 
Size at baseline 223 227 190 413 
Size at end of treatment** 154 160 115 269 
Male:Female*** 105:84 94:100 79:63 184:147 
Median age 64 64 62 (n=7)* 63 (n=14)* 
Median % weight loss 
(pre-treatment) 
17.7 (n=7)* 11.8 - 14.6 
(n=7)* 
13.5 (n=6)* 16 (n=13)* 
Mean period of time over 
which weight loss occurred 
(months) 
6 (n=3)* 6 (n=3)* 4.1 (n=4)* 4.9 (n=7)* 
SUPPLEMENT USED 
- EPA capsules 
- ENS 
 
3 
4 
 
- 
- 
 
7 
2 
 
10 
6 
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which represented 0.9% of the total study population and 1.2% of the Treated 
population. These studies were included in the data analysis to avoid 
excluding 18.6% of the total study population and 22% of the Treated 
population who did have solid tumours, thereby potentially influencing the 
results of this review. 
 
Table 3.3 A detailed representation of the tumour sites of the study population  
CONTROLLED STUDIES (n= 7) UNCONTROLLED STUDIES 
(n=9) 
TOTAL (n=16) TUMOUR SITE 
TREATED CONTROL TREATED TREATED 
ONLY* 
- pancreas 
- genitourinary 
- breast 
- gastrointestinal 
- lung 
- liver 
- colorectal/anal 
- renal 
- head and neck 
- sarcoma 
- neuroendocrine 
- myelodysplastic 
syndrome 
- myeloma 
- carcinoid 
- haematologic 
- mesothelioma 
- unknown 
144 
7 
9 
25 
12 
4 
1 
1 
1 
1 
0 
0 
 
0 
0 
0 
0 
2 
142 
5 
12 
22 
12 
3 
0 
0 
0 
2 
0 
0 
 
0 
1 
1 
1 
5 
127 
2 
3 
2 
18 
2 
10 
3 
1 
3 
3 
2 
 
1 
0 
2 
0 
8 
271 
9 
12 
27 
30 
6 
11 
4 
2 
4 
3 
2 
 
1 
0 
2 
0 
10 
 
* These totals are only approximate totals as some studies classified tumour sites at baseline whereas other studies 
used the data collected at the end of the trial 
 
A graphical representation (Figure 3.1) of the size of the study populations of 
the 16 studies shows the decrease in sample size in the Treated and Control 
groups from baseline to the end of the period of intervention. Interestingly, 
only 1 of the 16 studies had Treated and Control group sizes that exceeded 
50 patients. Missing data from 2 of the 16 studies enabled only baseline 
sample sizes to be represented. 
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Figure 3.1 Study population sizes of the included studies at baseline and after intervention  
Study ID – Study Identification number 
 
3.3 CHARACTERISTICS OF THE SUPPLEMENTS USED AND TRIAL 
PERIOD 
In studies (n=15) that specified the period of intervention, the duration ranged 
from 2 – 24 weeks (mean and median duration of the trials was 8.2 – 8.5 
weeks and 8 weeks respectively). 
 
The minimum duration that the enriched nutritional supplement (ENS) was 
used was 3 weeks and the maximum was 8 weeks. In comparison, the 
minimum duration that the capsules / emulsion were used was 2 weeks and 
the maximum was 24 weeks. Interestingly, in the latter study, Barber MD et al 
(S23)34 there was 100% compliance of the prescribed regime. 
 
Ten of the included studies used fish-oil capsules as their EPA supplement; 
the remaining 6 studies used a nutritional supplement enriched with n-3 fatty 
acids (Table 3.4).  
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Table 3.4 The type of supplement used according to study design 
 ENRICHED NUTRITIONAL 
SUPPLEMENT 
(n=6) 
CAPSULES / EMULSION* 
(n=10) 
Phase I trials 2 2 + 1* 
Phase II trials 2 4 
Phase III trials (RCT) 2 3 
* 1 study made use of an n-3 fatty acid emulsion 
RCT – Randomised Controlled Trials 
  
Of the 16 studies, the 6 studies that used the ENS appeared to have used the 
same product and prescribed the same volume of this supplement per day. 
The target intake was 2 x 237ml cans per day, providing 2.2g EPA per day. 
The average actual intake that was reported by 5 of the studies ranged from 
1.4 – 1.9 x 237ml per day, which provided 1.25 – 2.0g EPA per day. One 
study did not report the actual intake of the supplement during the trial period 
(Table 3.5). 
The remaining 10 studies used a variety of EPA supplements. They were 
introduced and administered either as fish oil capsules or as a liquid emulsion 
in varying doses that ranged from 0.34-36 g EPA per day and was increased 
at weekly intervals until a maintenance dose was achieved. Although the 
maximum dose tolerated was 36g/d (Barber MD et al (S23)34), only 2 patients 
in this particular study  managed to achieve this dose and they were only able 
to tolerate it for 1 week (specific reasons for this dose not being tolerated for 
longer were not reported). Compliance with the prescribed trial amount ranged 
from 50 – 100% (Figure 3.2). In the two studies of Burns CP et al (S22,S63)38, 
39, patients managed to consume more than the prescribed dose; the actual 
intake was therefore 127% and 300% of the target intake respectively (Table 
3.5).  
 
Although both types of supplementation had good compliance during the 
study periods, it appeared that a higher dose of EPA was tolerated with the 
capsules than with an ENS drink.  
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Figure 3.2 The actual intake of EPA versus the target intake of EPA 
 
Table 3.5 The target intake compared to the actual intake of the EPA supplements 
STUDY ID / 
TRIAL 
RECOMMENDED INTAKE OF  
EPA / d (g) 
ACTUAL INTAKE OF  
EPA / d (g) 
COMPLIANCE (%) 
ENS 
S3   / RCT 2.2g 1.54g 70% 
S79 / RCT 2.2g 2.0g 91% 
S21 / PI 2.2g 1.4 – 2.2g 63 – 100% (median 95%) 
S23 / PI 2.2g 1.32 – 2.2g 60 – 100% 
S10 / PII 2.2g 1.4 – 2.2g 63 – 100% (median 95%) 
S60 / PII 2.18g Not reported - 
CAPSULES 
S6  / RCT 3.24g 1.76g 54% 
S17 / RCT 6.0g 5.4 – 6.0g 90 – 100% 
S91 / RCT 3.06g Not reported ?100% 
S13 / PI 4.5 – 36g 18 – 36g 50 – 100% 
S22 / PI 0.0378g /kg/d 
~ 2.34g /d* 
0.0378 – 0.1134g/kg/d 
~ 2.34g – 7.03g /d* 
100 – 300% 
S28 / PI 1 – 6g 1-6g 100% 
S20 / PII 1.0 – 6.0g Not reported - 
S63 / PII 0.067g/kg/d 
~ 4.3g / d* 
0.067 – 0.086g/kg/d 
~ 4.3 – 5.5 g / d* 
100 – 127% 
S31 / PII 0.34 – 2.72g 2g 74% 
S71 / PII 2.2 – 2.9g & 6g 2.2 – 6g 100% 
*To calculate the amount of EPA/day, the median weight of patients at entry to the study was used 
Study ID – Study Identification number 
EPA – Eicosapentaenoic acid 
ENS – Enriched nutritional supplement 
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 RECgpd:ACTUALgpd:  r2 = 0.9870;  r = 0.9935, p = 0.0000
Stellenbosch University http://scholar.sun.ac.za
 35
3.4 CLINICAL OUTCOMES  
3.4.1 Weight change 
Fourteen studies measured the change in weight following supplementation 
with either ENS or capsules (Appendix 6.9.4). There was baseline data for 11 
of the 16 studies; unfortunately only 7 studies provided complete weight data 
for during or after intervention (Table 3.6).  
 
Table 3.6 – Summary of weight data recorded by included studies 
WEIGHT (kg) Study ID INTERVENTION 
0 wks 3 wks 4 wks 7 wks 8wks 12wks 24wks 
S3 ENS 60.3  60.05*  59.8*   
S21 ENS 55.2 56.2      
S23 ENS 55.2 56.2  57.2    
S60 ENS 55.0 **      
S6 Capsules 60.8    60.83   
S17 Capsules 67     **  
S20 Capsules 66.8  66.0  65.2 65  
S22 Capsules 62    **   
S31 Capsules 62  63   62  
S63 Capsules 64  **     
S71 Capsules 68.8  66.0  65.2 64.5 62.2 
* Significant change in weight reported by investigators of that particular study 
** Weight at the end of intervention not available 
Study ID – Study Identification number 
ENS – Enriched nutritional supplement 
 
The mean weight at baseline of the Treated group was 61.6 kg (SD 4.92, 
n=11 of 16 studies) and that of the Control group was 61.0 kg (SD 1.87, n=4 
of 16 studies). The mean weight of the Treated group after intervention was 
61.7 kg (SD 2.75, n=8 of 16 studies) and that of the control group was 60.5 kg 
(SD 0.45, n=2 of 16 studies). The change in weight in the experimental group 
was 0.1kg and that of the control group was -0.5kg.  
 
Figures 3.3 and 3.4 provide a graphical representation of the weight observed 
before and after supplementation with EPA. The weight has been represented 
using the reported baseline weight of the included study and the calculated 
mean of the weight measurements taken and reported during and after the 
period of intervention. The studies without graphical representation are those 
that did not report adequate data for any calculation to be made.  
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Figure 3.3 The weight in the Control and Treated groups before and after intervention 
Study ID – Study Identification number 
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Figure 3.4 The  weight in the EPA supplemented group before and after supplementation 
 
Twelve of the 16 studies did, however, report the change in weight that 
occurred, although only 8 of the 16 studies had sufficient data to calculate the 
change in weight. Seven of the 16 studies reported the total weight change, 
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and 5 of the 16 studies reported the rate of weight change observed following 
supplementation with EPA (Tables 3.7.1 and 3.7.2 respectively) 
 
Table 3.7.1 –Total weight change reported following supplementation with EPA 
STUDY ID INTERVENTION DURATION OF 
INTERVENTION  
(weeks) 
MEDIAN WEIGHT 
CHANGE  
(kg) 
S10 ENS 3 +1.0 
S21 ENS 3 +1.0* 
S23 ENS 3 
7 
+1.0 * 
+2.0 * 
S79 ENS 8 0.0 
S6 Capsules 8 +0.03 
S63 Capsules * - 0.8 
S91 Capsules 6 0.0 
*Significant change in weight reported by investigators of that particular study 
Study ID – Study Identification number 
ENS – Enriched nutritional supplement 
 
Table 3.7.2 – The rate of weight change reported following supplementation with EPA 
STUDY 
ID 
INTERVENTION DURATION OF 
INTERVENTION  
(weeks) 
MEDIAN RATE OF 
WEIGHT CHANGE  
(kg / mo) 
S3 ENS 8 -0.25* 
S60 ENS 3 +1.0* 
S20 Capsules 0 
4 
8 
12 
-2.0 
+0.5 
+0.2 
+0.3 
S31 Capsules 12 +0.3 
S71 Capsules 0 
4 
8 
12 
24 
-2.2 
+0.75 
+0.2 
+0.3 
+0.1 
*Significant change in weight reported by investigators of that particular study 
Irrespective of how the weight change has been measured, the change 
following intervention with ENS and capsules was minimal, with only 5 of the 
16 studies measuring a change that was statistically significant. Reflecting on 
the data in Tables 3.7.1 and 3.7.2, the greatest change in weight appeared to 
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occur within the first three to four weeks with both types of interventions. 
Similarly, the longer the period of intervention, the smaller the change in 
weight appeared to become. 
 
The study of Burns et al (S63)39 described the weight change in their study 
population in more detail. The majority of their sample maintained their weight 
over a median period of 1.2 months using capsules as the means of 
intervention. Table 3.8 is adapted from Burns et al (S63)39 and summarises 
the change in weight that was observed in that study.   
 
Table 3.8 – The results of the weight change observed in the study of Burns et al (S63)39 
WEIGHT 
CHANGE 
DEFINITION OF WEIGHT CHANGE NO. OF PATIENTS 
(%) 
Gained weight 5% body weight gain / reached 
pre-morbidity weight 
6 (17) 
Lost weight ≥ 5% body weight 6 (17) 
Stable weight Weight gain ≤ 5% or weight loss < 5% 24 (66) 
Unevaluable  7 (-) 
Total Study Population 43 (-) 
Source: Burns CP et al,200439  
 
3.4.2 Body composition 
3.4.2.1 Lean body mass (LBM) 
Lean body mass was measured in 5 of the 16 studies. All 5 studies used 
bioelectrical impedance to measure body composition. LBM was calculated 
assuming lean tissue contains 73% water. Of the 5 studies, 2 were 
uncontrolled and 3 were controlled studies. The uncontrolled studies reported 
a change in LBM that was statistically significant (p < 0.05). The controlled 
studies, however, reported that there was no statistically significant change in 
LBM within either the treated group or the control group, or even between the 
two groups (Figure 3.5). 
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Figure 3.5 The change in LBM after a period of intervention 
* Studies that reported a significant change in LBM in that particular study 
 
The analysis performed in this study on the combined LBM data of 3 studies 
showed that there was no significant difference (p=0.496, t=0.825, n=3 
studies) between the EPA supplemented group and the controls following 
supplementation.  
 
Furthermore, this analysis has also shown that there was no significant 
difference (p=0.841, t=0.228, n=3 studies) in LBM in the control group 
following supplementation. However, the combined analysis of the EPA 
supplemented groups in these 5 studies showed that there appears to be a 
significant change (p=0.03, t=3.286, n=5 studies) in LBM following 
supplementation. 
 
3.4.2.2  Fat mass (FM) and Body water (BW) 
There was no significant change in fat mass in the two studies that did 
measure this outcome. 
Both of these studies used ENS. The change that was measured and reported 
in these studies ranged from -0.2 - +0.2 kg over a period of 3 – 7 weeks.  
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Similarly, there was no significant change (p value not reported) in the 
percentage body water in the three studies that did measure this outcome. 
The change that did occur ranged from -1.8% - +1.0% over a period of 7-12 
weeks. Two of the studies used capsules and one used ENS.  
 
The lack of adequate data for the above mentioned outcomes prevented a 
combined analysis from being performed. 
 
Only one40 of the 16 studies measured all three of these outcomes. 
Interestingly, this study reported that there was a significant increase in body 
weight and lean body mass, whereas the change in fat mass and percentage 
body water was not statistically significant (p value not reported). Although fat 
mass appeared to increase in relation to the increase in body weight, the 
percentage fat mass actually decreased. 
 
3.4.3 Appetite 
 Measuring the effect of n-3 supplements on appetite was not considered by 
many of the studies; only 2 of the 16 trials measured the change in appetite 
following EPA supplementation. Both studies reported a change in appetite 
that was not statistically significant (p value at end of trial not reported). The 
lack of adequate data prevented any analysis from being performed in this 
study. 
 
3.4.4 Dietary intake 
3.4.4.1 Energy Intake 
 Total energy intake per day (kcal/d) was measured by 6 of the 16 studies, 4 
of which were RCTs, 1 Phase I trial and 1 Phase II trial.  Within the 6 studies, 
3 used ENS and 3 used capsules. Three of the studies had baseline and mid-
study data and the remaining 3 studies had baseline and end of study data. 
Three-day food diaries were used by 4 of the 6 studies, 1 of the 6 studies 
used diet records, and 1 of the 6 studies did not specify the method that they 
used to record dietary intake.  
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With the exception of one study, there was an increase in energy intake 
following EPA supplementation, which ranged from 51 – 474 kcal/day. The 
mean change in intake was 139.3 kcal/d. In comparison, two of the control 
groups reported a decrease in energy intake and two reported an increase in 
energy intake per day.  The mean change in intake was, however, -45 kcal/d. 
More specifically there was a mean 200 kcal/d increase in energy intake in the 
three studies that used ENS compared to a mean 79 kcal/d increase in energy 
intake in the studies that used the capsules. Despite these observations, it 
must also be noted that the trials vary in trial duration (Table 3.9). 
 
Table 3.9 – A summary of the change in total energy intake per day after EPA 
supplementation 
DIETARY INTAKE – KCAL/D 
BEFORE DURING AFTER 
CHANGE IN 
INTAKE- KCAL/D 
ID 
(DURATION 
OF TRIAL) 
INTERVENTION 
E C E C E C E C 
S3     (8wks)* ENS 1504 1613   1281 1237 -223 -376 
S79   (8wks) ENS 1574 1814   2048 1980 +474 +166 
S6     (2wks) Capsules 1386 1349   1437 1292 +51 -57 
S17 (12wks) Capsules 1964 1459 2098.6 
(1wk) 
1546.2   +134.6 +87.2 
S23   (7wks)* ENS 1450  1798 
(3wks) 
   +348  
S20 (12wks) Capsules 1777  1828 
(4wks) 
   +51  
          
MEAN  1609 1558.8 1908.2 1546.2 1588.7 1503 139.3 -45 
* Significant change in kcal/d intake reported by the investigators of the particular study 
EPA – Eicosapentaenoic acid 
Study ID – Study Identification number 
ENS – Enriched nutritional supplement 
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Figure 3.6 The energy intake of the Control and Treated group before and after the 
intervention 
 
The analysis of the combined data available for the total energy intake per day 
showed that there was no statistical difference between the EPA 
supplemented group and the controls (p=0.156, t= 2.239, n=3 studies, paired 
t-test) and no significant difference between baseline and end of treatment 
total energy intake following supplementation with EPA (p=0.261, t= 1.296, 
n=5 studies, paired t-test). No further analysis was possible. 
 
3.4.4.2 Protein Intake 
Only 2 of the 16 studies measured protein intake per day. Both of the studies, 
namely Fearon et al (S3)35 and Moses et al (S79)19, used ENS and reported 
that there was a significant change in protein intake per day; however, the 
study of Moses et al (S79)19 reported the change as an increase in intake, 
whereas the study of Fearon et al (S3)35 reported the change as a decrease in 
protein intake (Table 3.10).  
 
The combined analysis of this data showed that there was no significant 
difference (p=0.263, t= 2.286, n=2 studies, paired t-test) between the EPA 
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supplemented group and the controls; additionally, there was no significant 
change (p=0.683, t=0.541, n=2 studies, paired t-test) in protein intake from 
baseline to the end of supplementation with EPA. No further analysis was 
possible. 
 
Table 3.10 – A summary of the change in protein intake per day after EPA supplementation 
DIETARY INTAKE  
(grams protein / day) 
CHANGE IN 
INTAKE- g/day 
BEFORE AFTER  
STUDY ID 
(duration of 
trial) 
INTERVENTION 
E* C** E* C** E* C** 
S3 (8wks) ENS 60 63 52 46 -8 -17 
S79 (8wks) ENS 57 73 84 77 27 4 
* E represents the treated group that received the ENS 
** C represents the control group that received a standard nutritional supplement 
 
The studies of Fearon et al (S3)35 and Moses et al (S79)19 recorded and 
reported energy and protein intake in more detail than as discussed above. 
These studies specified the protein and energy contribution the ENS made 
towards the total energy and protein intake.   
 
By deducting the contribution made by the ENS and NS, the actual change in 
dietary intake can be assessed. Over a period of 8 weeks, there was a 
decrease in total dietary energy intake and protein per day in both the treated 
and control groups. The use of the supplements in both groups provided an 
additional 23 -28% energy/day and approximately 31 - 36% protein /day. This 
contribution therefore resulted in an overall increase in the total dietary intake 
per day (Tables 3.11-3.14).  
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Table 3.11 –Total energy intake at baseline and after 8 weeks of supplementation  
AFTER 8 WEEKS OF SUPPLEMENTATION DIETARY INTAKE 
WITHOUT 
SUPPLEMENTS AT 
BASELINE (kcal/d) 
DIETARY INTAKE 
WITHOUT 
SUPPLEMENTS 
 (kcal/d) 
DIETARY INTAKE 
WITH 
SUPPLEMENTS 
(kcal/d) 
STUDY 
ID 
E (ENS) C (NS) E (ENS) C (NS) E (ENS) C (NS) 
S3 1504 1613 1280 1237 1728 1681 
S79 1574 1814 1472 1519 2048 1980 
Study ID – Study Identification number 
ENS – Enriched nutritional supplement,  NS – Nutritional Supplement 
 
Table 3.12 – Protein intake at baseline and after 8 weeks of supplementation  
AFTER 8 WEEKS OF SUPPLEMENTATION DIETARY INTAKE 
WITHOUT 
SUPPLEMENTS AT 
BASELINE (g/d) 
DIETARY INTAKE 
WITHOUT 
SUPPLEMENTS 
(g/d) 
DIETARY INTAKE 
WITH 
SUPPLEMENTS 
(g/d) 
STUDY 
ID 
E (ENS) C (NS) E (ENS) C (NS) E (ENS) C (NS) 
S3 60 63 52 46 75 69 
S79 57 73 54 53 84 77 
Study ID – Study Identification number 
ENS – Enriched nutritional supplement, NS – Nutritional Supplement 
 
Table 3.13 – A summary of the change in dietary intake after 8 weeks of supplementation  
CHANGE IN DIETARY INTAKE 
WITHOUT SUPPLEMENTS 
CHANGE IN DIETARY INTAKE WITH 
SUPPLEMENTS 
Kcal/d Protein g/d Kcal/d Protein g/d 
STUDY 
ID 
E 
(ENS) 
C (NS) E 
(ENS)
C (NS) E 
(ENS) 
C (NS) E 
(ENS) 
C (NS) 
S3 -223 -376 -8 -17 +224 +68 +15 +6 
S79 -102 -295 -3 -20 +474 +166 +27 +4 
Study ID – Study Identification number 
ENS – Enriched nutritional supplement, NS – Nutritional Supplement 
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Table 3.14 – The % contribution the supplements made to the total dietary intake 
% ENERGY (kcal/d) % PROTEIN – g/d STUDY ID 
E (ENS) C (NS) E (ENS) C (NS) 
S3 25.9 26.4 30.7 33.4 
S79 28 23.3 35.7 31.2 
Study ID – Study Identification number 
ENS – Enriched nutritional supplement, NS – Nutritional Supplement 
 
3.4.5 Energy expenditure 
Indirect calorimetry was used by 6 of the 16 studies to calculate resting 
energy expenditure (REE). Three of the studies used ENS and three used 
capsules. The measurements were expressed either as kilocalories per day 
(kcal/d) and / or as kilocalories per kilogram per day (kcal/kg/d). 
 
From the data provided in the studies, there was no obvious pattern in the 
change in resting energy expenditure and no conclusions can be drawn from 
the statistical significance reported by the various studies. Two of the studies 
did not report REE as kilocalories per day; thus the mean baseline weight of 
these samples and the kilocalories per kilogram per day was used to calculate 
the kilocalories per day, thereby enabling better comparisons to be made 
between the studies. The results of such a calculation can only be used for 
descriptive purposes 
From the data collected there does appear to be a decrease in the total 
energy expenditure following supplementation with EPA. There is only a 
4kcal/d difference in the change in resting energy expenditure between ENS 
and capsules (Table 3.15). Figure 3.7 is a graphical representation of the 
resting energy expenditure following EPA supplementation. Only those 
studies that provided adequate data are represented on the graph. 
 
The analysis performed on the combined data of the 6 studies showed that 
there was, however, no significant difference in resting energy expenditure 
expressed either as kcal / day (p=0.216, t= -1.562, n=4 studies) or as 
kcal/kg/day (p=0.23, t= -1.414, n= 5 studies, paired t-test, paired t-test) from 
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baseline to the end of the treatment period following supplementation with 
EPA. No further analysis was possible owing to the lack of data. 
 
Table 3.15 – The change in resting energy expenditure per day after EPA supplementation 
Study ID  
(study design) 
Baseline Energy 
Expenditure 
 kcal/day 
End of treatment 
Energy Expenditure 
(kcal/day) 
 ENS Capsules ENS Capsules 
Change in 
energy 
expenditure 
(kcal/d) 
S21 (P1) 1354  1295  -59 
S23 (P1)** 1339  1303  -36 
S79 (RCT) 1387  1386  -1 
S17 (RCT)*  1494  Not reported - 
S31 (P2)*  1550  1612 118 
S71 (P2)  1815  1570 -245 
      
Mean kcal / day / 
supplement 
1360 1619 1328 1591  
Mean kcal / day 1489.8 1433.2  
* The studies where the kcal/d was calculated from kcal/kg/d data using the baseline weight 
** Significant change reported by investigators of this particular study 
Study ID – Study Identification number, ENS – Enriched nutritional 
supplement
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Figure 3.7 Energy expenditure in the Treated group after EPA supplement 
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3.4.6 Functional status 
Functional status was measured in 8 of the 16 studies, and 5 of the studies 
used the Karnofsky assessment tool. The remaining three used the WHO 
performance status questionnaire, FAACT and FACT-G questionnaires and 
the physical activity level respectively. The Edmonton Functional Assessment 
Tool (EFAT) was used with the Karnofsky performance status in one of the 
trials. 
 
Only 3 studies had complete data, 2 reported only the change in functional 
status, 1 reported only baseline data, 1 had incomplete data and 1 did not 
report any data on functional status. 
 
Bruera et al (S6) 41 measured functional status at baseline and at the end of 
the trial using KPS and EFAT. At baseline, the difference between the 
experimental group and the control group was significant (p=0.05) with the 
KPS but not with the EFAT. On completion of the trial, the changes in the KPS 
and EFAT in both groups were not statistically significant (p value was not 
reported).  
 
Fearon et al (S3)35 measured KPS at baseline and on completion of the trial.  
However, it was only reported that the change in functional status was not 
significant (p value was not reported).  
 
Barber et al, 2001 (S13)42 used the KPS, but unfortunately no details were 
reported. 
 
Barber et al, 1999 (S23)40 measured functional status at baseline, at 3 weeks 
and at 7 weeks, using KPS. There was a statistically significant improvement 
in functional status at 3 (p= 0.0047) and 7 (p=0.046) weeks compared to 
baseline. 
 
Burns et al (S63)39 used FAACT/FACT-G to measure functional status. There 
was a positive change recorded in both questionnaires, but it was not reported 
if these changes were significant or not.  
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Wigmore et al (S20)43 used the WHO performance status and measured 
functional status at baseline and monthly thereafter. The results showed that 
there was no statistically significant change in functional status (p value not 
reported).   
 
Using total energy expenditure and resting energy expenditure, Moses et al 
(S79)19 were able to calculate the physical activity. The change in the Treated 
group was greater than the change in the Control group. 
 
Gogos et al (S91)44 also used the KPS to measure functional status. Within 
the experimental and control groups the researchers distinguished between 
malnourished and well-nourished patients. The only change that was reported 
was the significant improvement in the KPS score in the malnourished 
experimental group following 6 weeks of supplementation with capsules.  
 
The only functional status data that could be used for the paired t-test in this 
study was for the KPS. The result of this analysis showed that there was no 
significant change (p= 0.231, t= 1.704, n=3 studies) in functional status using 
the KPS in the EPA supplemented group. In summary, irrespective of the 
assessment tool used, a change in functional status was reported by 7 of the 
8 studies. Three of these studies reported the change as statistically not 
significant, 2 of the studies reported the change as statistically significant and 
3 did not report on the significance of the change.  
 
3.4.7 Acute phase response 
Seven of the 16 studies used C-reactive protein to assess the change in acute 
phase response. One study used other markers to measure the acute phase 
response whilst the remaining 8 studies did not measure the change in acute 
phase response (Appendix 6.9.9).  
 
After four weeks of supplementation with fish oil capsules, a significant 
reduction in CRP levels was noticed in three of the trials (Figure 3.8). This 
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reduction was, however, not maintained and after 12 weeks of 
supplementation, the CRP levels had increased again. There was no change 
in CRP levels in the study using ENS.  
 
 
Figure 3.8 – Outcome of CRP Measurements 
 
The combined analysis of the available data in this study showed that there 
was no significant change (p= 0.542, t= -0.686, n=4 studies, paired t-test) in 
CRP levels following supplementation with EPA. 
 
3.4.8 Quality of life 
With the exception one study, none of the studies investigated aspects 
regarding quality of life and the use of ENS and capsules (Appendix 6.9.11). 
 
The study that did investigate quality of life measured this outcome using the 
EORTC and EuroQoL questionnaires and only reported that there was no 
significant differences between the baseline data and the data collected at the 
end of the study. Unfortunately, this data was not published. The investigators 
were contacted for these details but no response was received. 
  
3.4.9 Safety 
Details of the adverse effects noted following the consumption of the fish oil 
capsules and the ENS were reported by 7 of the 16 studies (Table 3.16). The 
remaining 9 studies either did not record this data or failed to report these 
 
CRP Measured 
 
1 x RCT 
 
2 x Phase I trials 
 
4 x Phase II trials 
 
- Change not significant - No change 
- Significant 
reduction at 4wks 
- No data (2) 
- Significant 
reduction at 4 wks 
(2)
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details. It is not necessarily an indication that no adverse effects were 
experienced (Appendix 6.9.11). 
 
Patients in the studies using the EPA capsules experienced the majority of the 
adverse effects. Participants using ENS experienced fewer adverse effects 
 
Table 3.16 A summary of the adverse effects reported following the use of EPA supplements 
SYMPTOM Adverse effects 
reported with the 
use of ENS (n) 
Adverse effects 
reported with the use 
of CAPSULES (n) 
TOTAL (n) 
Taste changes  35 +* 35+* 
Belching  26 26 
Nausea  19 19 
Flatulence  18 18 
Body Odour  14 14 
Diarrhoea  8+* 8+* 
Emesis  8 8 
Steathorrea 3 4 7 
Sensation of 
fullness 
 4 4 
Vomiting  3 3 
Constipation  3 3 
Abdominal pain  3 3 
Dyspepsia  2 2 
    
* Symptoms specified but number not specified 
n - represents the number of patients who experienced the adverse effect 
ENS – Enriched nutritional supplement 
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 4. DISCUSSION  
The complex and multi-factorial nature of cancer cachexia and the inability of 
conventional nutrition intervention to reverse or attenuate the effects of this 
syndrome have driven investigators to consider new therapies and 
approaches to manage the syndrome of cancer cachexia. One such approach 
is to utilise the apparent anti-cachectic and anti-tumour properties of 
eicosapentaenoic acid (EPA), an n-3 fatty acid of fish oil origin. The benefits of 
such actions suggest that EPA could have the potential to promote weight 
maintenance, improve dietary intake, inhibit tumour growth and ultimately 
have an influence on patient survival30 32.  
 
Initially, this study was only aiming to establish the safety and efficacy of a 
nutritional supplement enriched with EPA in patients with cancer cachexia. 
This was, however, changed to incorporate studies making use of fish oil 
capsules as a means of EPA supplementation. The objectives of this review 
considered those outcomes that have the greatest impact on a cancer 
patient’s quality of life and potential survival. Interestingly, despite not 
restricting the search period, all relevant studies identified were within the 
specified period of 1994 – 2004. Date of publication therefore had little 
influence on the inclusion and exclusion of studies in this review.  
 
4.1 The effect of eicosapentaenoic acid (EPA) on weight 
The weight attenuation or reversal of weight loss seen with EPA 
supplementation is associated with EPA’s ability to modulate PIF and LMF 
activity and prevent protein and fat breakdown.34, 35 Similarly, with these 
effects, there would be the expectation that EPA supplementation would also 
have beneficial effects on protecting lean body mass and fat reserves. 
 
This study indicates, however, that the total weight change that does occur is 
minimal and although a few studies showed an initial significant change in the 
rate of weight loss, this appears to be short-lived. Disappointingly, despite 
providing additional calories, the use of an ENS only had the effect of weight 
stabilisation.35  
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4.2 The effect of eicosapentaenoic acid (EPA) on body composition 
Encouragingly, despite the small number of studies that measured changes in 
body composition, there is an indication that EPA supplementation 
significantly improves lean body mass. Although changes were observed in fat 
mass and body water, there is insufficient data to provide further insight or 
comment at present, although previous studies with enteral and parenteral 
nutrition in cancer patients have suggested that the change in weight can be 
attributed to a change in the percentage body water, Barber et al (S23)40, 
however, have shown that there is no change in hydration status, and that the 
change in weight is the result of a significant increase in lean body mass, 
albeit a small increase. Further studies support these findings that the weight 
gain seen is not as a result of an increase in the percentage body water40, 45.  
 
4.3 The effect of eicosapentaenoic acid (EPA) on appetite 
Given the lack of available data, establishing or commenting on the effect of 
EPA on appetite in this study is limited. Previous studies have had contrasting 
results. Appetite appears to increase soon after supplementation is initiated, 
which could contribute to the increase seen in dietary intake; however Bruera 
et al (S6)41 found no improvement in appetite following supplementation, 
although it has been questioned as to whether or not higher doses of EPA 
may be more effective to improve appetite, but this may have an implication 
on the tolerance thereof in cancer patients40, 41.  
 
4.3 The effect of eicosapentaenoic acid (EPA) on dietary intake 
It remains a very difficult task for the dietician and clinician to encourage a 
cachectic cancer patient to drink a nutritional supplement as well as increase 
their dietary intake20. In the studies that measured this outcome, there 
appeared to be a great variation in the change in dietary intake with regards to 
energy and protein intake. As this was not necessarily the main objective of 
many of the studies, the approach to recording intake may have varied 
greatly, which could have had an influence on the accuracy of the results 
reported. Interestingly, contradictory results of some studies raise the issue 
about how beneficial nutritional supplementation is. Barber et al (S23)40 found 
that the significant increase in dietary intake in their study was not solely due 
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to the additional calories from the EPA enriched nutritional supplement. 
Patients managed to improve their total dietary intake following the use of the 
supplement40. In comparison, the change in intake reported by Fearon et al 
(S3)35 and Moses et al (S79)19 found that, although there is an overall 
increase in total intake per day with the supplements, the actual dietary intake 
decreases19, 35. This could be attributed to disease progression and general 
deterioration of the cancer patient, in which case the additional calories of the 
supplements are beneficial. Alternatively, the increased intake of the 
supplements could be suppressing actual dietary intake, in which case their 
consumption may be of little value. The increase in total intake and changes 
seen in physical activity and lean body mass could be suggestive of the fact 
that with EPA supplementation there is greater utilisation of protein and 
energy for energy production, as opposed to energy storage, which could be 
related to the role of EPA on mediator pathways19. 
 
4.4 The effect of eicosapentaenoic acid (EPA) on energy expenditure 
Barber et al (S21)46 have shown in their study that EPA supplementation is 
able to reduce resting energy expenditure in cancer patients, although 
Zuijdgeest- Van Leeuwen et al (S17)45 were unable to repeat these results. 
Their study showed no change in REE45, 46.  Despite the fact that this study 
has shown no significant effect of supplementation on energy expenditure, it 
does appear that more studies than not have noticed a reduction in REE. 
 
4.5 The effect of eicosapentaenoic acid (EPA) on functional status 
The great variation of functional status assessment tools used by the included 
studies and lack of adequate data have also made it very difficult to accurately 
assess the effect of EPA supplementation on functional status. There does, 
however, appear to be a small but positive improvement in functional status 
following EPA supplementation. 
 
4.6 The effect of eicosapentaenoic acid (EPA) on acute phase response 
Wigmore et al (S20)43 concluded that the data from their study could support 
the potential of EPA to modulate the acute phase response following the 
significant reduction in CRP after 1 month of EPA supplementation43. Barber 
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et al have also observed that an EPA enriched nutritional supplement can 
help prevent progression of the acute phase response in patients with 
pancreatic cancer43. This study has been unable to show any significant effect 
on CRP levels, although it does appear that there is an initial improvement, 
but it is not maintained beyond 4 weeks of supplementation. 
 
4.7 The safety of eicosapentaenoic acid supplementation 
Patients with advanced cancer are able to tolerate large doses of fish oil 
capsules with only minor side effects. Fearon et al have also demonstrated 
that large doses of EPA are well tolerated as an emulsion. The maximum 
tolerated dose could be influenced by several factors such as pancreatic 
insufficiency and by the types and amounts of other fats taken in the diet38, 42. 
This data has little impact in this study as there hasn’t been adequate 
information to relate these side effects to aspects such as compliance or drop-
out rate from the studies. It would, however, have been of value to establish 
which method of supplementation is better tolerated and associated with the 
least amount and severity of side effects, as this will definitely have an impact 
on the efficacy of future intervention with EPA supplements. 
 
It is well known that pancreatic cancer has the greatest impact on nutritional 
status and is associated with rapid disease progression. The severity of the 
cachexia and high drop-out rate could be seen as a limiting factor regarding 
the lack of effect of EPA supplementation seen in some of the studies using 
only patients with pancreatic cancer. Furthermore, it must not be overlooked 
that despite all the evidence supporting the beneficial effects of EPA 
supplementation in CC, there is evidence available regarding the lack of effect 
of EPA on tumour growth, and suggesting that its use in the prevention of 
cancer cachexia could be limited by the tumour type and growth pattern47. An 
additional objective of this review was therefore to determine if tumour sites 
other than the pancreas have been considered. The lack of data allows this 
study only to list and state that other tumour sites have been included in trials 
using EPA supplements. Unfortunately it has not been possible to establish if 
there is a difference in effect between tumour sites following EPA 
supplementation. 
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Although EPA supplementation had positive effects on lean body mass, the 
lack of adequate symptom control and improvement of other nutritional 
variables may be a limiting factor in the therapeutic use of EPA supplements 
in patients with incurable progressive disease41.  Bruera et al (S6)41 have also 
concluded that the use of fish oil as an alternative or complementary therapy 
does not help to improve subjective or objective manifestations of cancer 
cachexia/ anorexia.41 Quality of life, the outcome that could best address the 
impact that supplementation, either as fish oil capsules or as an enriched 
nutritional supplement, has on patients with cancer cachexia, was not 
adequately investigated and / or reported on in the studies included in this 
study. 
 
Studies regarding the use of EPA supplementation have shown variable 
results, with few changes being significant. This could possibly be due to the 
limitations that many of the studies have with regards to the nature of the 
patient group and the rapid rate of disease progression with these patients, 
which will have a direct impact on drop-out rate and sample size and thus 
obscure results. Assessing the safety and efficacy of a product from individual 
studies with such limitations is difficult to establish, and for that reason one 
needs to consider a systematic review.  
 
Systematic reviews or meta-analyses are increasingly being used to identify, 
appraise, synthesize and, if possible, combine the results of relevant studies 
to arrive at conclusions which can facilitate policy and decision-making with 
regards to the use of an intervention48. 
 
This study was anticipating being able to combine the existing research 
regarding the use of EPA supplementation in patients with cancer cachexia 
and to provide greater clarity with regards to its safety and efficacy. The small 
number of studies meeting the inclusion criteria and the lack of adequate data 
has unfortunately meant that this study could not quantitatively analyse the 
evidence and assess for publication bias. Furthermore, this study only 
included trials published in English and together with factors such as the 
variations in trial designs, type of supplements used and the dose 
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administration thereof, the strength and interpretation of the evidence in this 
study has been influenced. A further limitation relates to the statistical analysis 
that has been incorporated. It must be reiterated that the statistical results are 
merely suggestive and by no means indicative of the effect of EPA 
supplementation on the outcomes reviewed. 
 
Although this study is unable to provide the quantitative evidence required to 
confidently advocate the use of EPA supplements in patients with cancer 
cachexia, it has certainly highlighted the difficulties and challenges that exist 
in managing the syndrome of cancer cachexia.  The lack of significant effect 
of an intervention such as EPA, which shows so much promise, should not 
dissuade ongoing research on this topic. The evidence accumulated in this 
study should first of all emphasise the need for collecting more complete data. 
Had the data in this review not been so incomplete, the statistical analyses 
might have produced a very different result. Furthermore, this data could be 
used to initiate research in areas that may result in the more effective use of 
EPA supplements in the future.  
 
Future considerations may include redirecting the use of EPA on specific 
tumour sites other than pancreatic, and reviewing the method, timing and 
route of administration of an oral EPA enriched nutritional supplement. These 
options can, however, only be implemented once there is a greater 
understanding of the mechanisms of cancer-associated wasting and the effect 
of intervention. A clearer definition of the different sub-groups of cancer 
cachexia, will make it possible to identify and characterize those patients who 
will be more likely to benefit from an intervention such as an EPA enriched 
nutritional supplement18, 49.  
 
Greater success may be achieved if the ENS is given earlier in the course of 
illness to prevent weight loss rather than waiting until it is too late and the 
manifestations of cancer cachexia are too severe to be reversed39. Earlier 
intervention may have a greater impact on maintaining well-being and 
functional status and thus play a role in preserving quality of life49. 
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A further suggestion regarding the future role of EPA supplementation is 
within the field of combination therapy33, 39. There are already current trials 
looking at the use of EPA enriched nutritional supplements in patients 
receiving chemotherapy50. There is also the possibility of combining 
pharmacologic management of cancer cachexia with EPA supplementation. 
Individualised dietary counselling has been found to promote the maintenance 
of adequate dietary intake and body weight, resulting in a marked reduction in 
the incidence and severity of anorexia and diarrhoea and improved quality of 
life51. Another recommendation could therefore be that greater emphasis is 
needed on improving dietary counselling and education with regards to dietary 
intervention and the use of EPA supplements.  
 
Ultimately it is also necessary to explore quality of life aspects in cancer 
patients in more detail. 
There is little information available in the literature regarding the impact of 
cancer cachexia on body image and quality of life52. Furthermore, it is 
important that, irrespective of the type of intervention used and the 
improvement in medical parameters it may produce, evaluating the impact 
that the method of intervention has on the cancer patient is not overlooked53. 
A lot of emphasis has been placed parameters such as achieving weight gain 
or improving anorexia but the actual patient benefit of such parameters is 
unclear49. Addressing the use of oral supplementation in cancer patients in 
more detail will definitely have an impact of the success and efficacy of any 
form of intervention. 
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CONCLUSION 
 
Although much of the data collected and analysed in this review are 
suggestive of the beneficial effects of EPA supplementation, there remains a 
significant lack of substantial evidence and conclusive statistical analysis to 
confirm that EPA supplementation, either as an enriched nutritional 
supplement or as fish oil capsules, is a safe and effective method of 
intervention in the management of patients with cancer cachexia. Future 
research should be directed at strengthening this evidence and considering 
alternatives to improve the efficacy of a supplement that possesses anti-
tumour and anti-cachectic properties and has the potential to improve quality 
of life for patients with cancer cachexia. 
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Incl / 
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Weight App / diet 
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En Ex 
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of Life 
Adverse 
Effects 
RCT / 
P1 /P2 
trials 
  
S1              
S2            E Commentary on S6 
S3 X  X X X X   X  RCT I  
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S5            E Review article 
S6 X X  X X   X X X RCT I  
S7            E Review article 
S8            E Review article 
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S15            E Could not be 
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S16            E Review article 
S17 X X    X     RCT I  
S18            E Review article 
S19            E Review article 
S20 X X  X  X X X  X P2 I  
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S25            E Review article 
S26 - X        X  E Animal study 
S27            E Review article 
S28 X X     X    P1 I  
S29              
S30  X         RCT E Animal study and no 
required outcome 
S31 X X  X  X X    P2 I  
S32            E Review article 
S33  X  X       RCT E Animal study 
S34            E Review article 
S35            E Could not be 
retrieved 
S36            E Not English 
S37            E Commentary on topic 
S38            E Review article 
S39            E Commentary 
S40            E Could not be 
retrieved 
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Study 
ID 
Population Intervention Outcome Study 
design 
INCL / 
EXCL 
Reason for exclusion 
 Adults with 
solid tumours 
n-3 
supple 
n-3 enriched 
nutritional 
supple 
Weight App / diet 
intake 
Body 
Compo 
Tumour 
/ APR 
Perform 
status 
Quality 
of Life 
Adverse 
Effects 
RCT / 
P1 / 
P2 trial 
  
S41            E Review article 
S42            E Review article 
S43            E Currently recruiting – no 
results 
S44            E Review article 
S45            E Review article 
S46            E Letter 
S47            E Sys review 
S48            E No results yet 
S49            E No results yet 
S50            E No results yet 
S51            E No results yet 
S52            E No results yet 
S53            E Unable to locate 
published study, no 
response from author 
S54            E  
S55            E No results yet 
S56            E No results yet 
S57            E No results yet 
S58            E No results yet 
S59            E No results yet 
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STUDY 
ID 
Population Intervention Outcome Study 
design 
INCL / 
EXCL 
Reason for exclusion 
 Adults with 
solid tumours 
n-3 
supple 
n-3 enriched 
nutritional supple 
Weight App / 
diet 
intake 
Body 
Compo 
/ En exp 
Tumour 
/ APR 
Perform 
status 
Quality of 
Life 
Adverse 
Effects 
RCT / 
P1 / P2 
trial 
  
S60 X  X X   X    P2 I  
S61  X          E Animal study 
S62            E Current trial / 
chemotherapy 
S63 X X  X     X  P2 I  
S64            E Abstract of S3 
S65            E Abstract of S3 
S66            E Abstract of S79 
S67            E Animal study 
S68 X  X X X    X X RCT E Not meeting criteria 
S69            E Animal study 
S70             Requested but not 
received 
S71 X X  X  X X    P2 I  
S72          X  E Animal study 
S73            E Review article 
S74            E Abstract 
S75            E Abstract S76 
S76            E Talk 
S77 X X  X  (X)  (X)   P1 E Not meeting criteria 
S78            E Review article, 1993 
S79 X  X (X) (X) X  X   RCT I  
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STUDY 
ID 
Population Intervention Outcome Study 
design 
INCL / 
EXCL 
Reason for 
Exclusion 
 Adults with 
solid tumours 
n-3 
supple 
n-3 enriched 
nutritional supple 
Weight App / 
diet 
intake 
Body 
Compo 
Tumour 
/ APR 
Perform 
status 
Quality of 
Life 
Adverse 
Effects 
RCT / 
P1 / P2 
trials 
  
S80 X           E n-3 supple not used 
S81            E Review article 
S82            E Review article 
S83            E Review article 
S84            E Abstract of 21 
S85            E Review article 
S86 X   X  X X    P1 E No supple used 
S87 X          P1 E n-3 supple not used, 
no required 
outcomes 
S88            E Animal study 
S89            E Animal study 
S90            E For lit r/v 
S91 X X  X   X X   RCT I  
S92            E For lit r/v 
S93              
S94            E Abstract of S71 
S95 - X  X        E Animal study 
S96              
S97            E Abstract & 1988 
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Appendix 6.4 Bibliographic information and study identification numbers of the excluded 
studies 
 
STUDY 
ID 
AUTHOR YEAR REASON FOR EXCLUSION 
S2 Belda IC, et al54 2003 Commentary on S6 
S4 Jho BS, et al55 2003 Review article on n-3 fatty acids 
S5 Tisdale MJ56 2003 Review article on cancer cachexia 
S7 Hardman WE57 2002 Review article on n-3 fatty acids 
S8 Tisdale MJ58 2002 Review article on cancer cachexia 
S9 Tisdale MJ59 2002 Review article 
S11 Barber MD24 2001 Review article on fish-oil enriched nutritional 
supplementation 
S12 Fearon KCH21 2001 Review article on cancer cachexia 
S14 Tisdale MJ60 2001 Review article on cancer cachexia 
S16 Babcock T, et al30 2000 Review article on n-3 fatty acids 
S18 Barber MD, et al10 2000 Review article on cancer cachexia 
S19 Tisdale MJ23 2000 Review article on cancer cachexia 
S24 Barber MD, et al31 1998 Review article on fatty acids 
S25 Tisdale MJ22 1999 Review article on wasting and cachexia 
S26 Griffini P, et al61 1998 Animal study 
S27 Puccio M, et al13 1997 Review article on cancer cachexia 
S30 Tisdale MJ62 1996 Animal study 
S32 Karmali R A, et al63 1996 Review article on n-3 fatty acids and cancer 
cachexia 
S33 Hudson EA64 1994 Animal study 
S34 Tisdale MJ65 1993 Review article  / > 10 years ago 
S37 Unknown66 2001 Commentary on fish oil 
S38 Fearon KCH27 2001 Review article 
S39 Unknown67 1998 Commentary on cancer cachexia 
S41 Mantovani G, et al53 2001 Review article on cancer cachexia 
S42 Barber MD20 2002 Review article on cancer cachexia 
S44 Ross JA, et al68 1999 Review article on n-3 fatty acids 
S45 Tisdale MJ69 1998 Review article on cachectic factors 
S46 Wigmore SJ, et al70 1994 Letter 
S47 Piotrowski P71 2002 Commentary 
S54 Fearon KCH  Protocol of S13 
S61 Beck SA, et al72 1991 Animal study and > 10 years ago 
S64 Fearon KCH, et al73 2001 Abstract of S3 
S65 Von Meyenfeldt M, et 
al74 
2002 Abstract of S3 
S66 Moses AWG, et al75 2001 Abstract of 79 
S67 Tisdale MJ32 1990 Animal study and >10 years ago 
S68 Jatoi A50 2004 Neo adjuvant treatment allowed – not meeting 
criteria 
S69 Hussey HJ76 1999 Animal study 
S72 Costelli P, et al47 1995 Animal study 
S73 Simopoulos AP33 2003 Review article on n-3 fatty acids 
S74 Kirk HJ, et al77 2002 Abstract, not humans 
S75 Voss AC78 1999 Abstract of S76 
S76 Voss AC79 1999 Talk 
S77 Gogos CA80 1995 Not meeting criteria 
S78 Tisdale MJ81 1993 Review article & > 10 years 
S80 Barber MD82 2004 No supplement used – not meeting criteria 
S81 Fearon KCH29 2002 Review article on n-3 fatty acids 
S82 Barber MD, et al11 2000 Review article on cancer and metabolism 
S83 Fearon KCH, et al83 1999 Review article on cancer cachexia 
S84 Barber MD, et al84 1999 Abstract of S21 
S85 Barber MD, et al85 1998 Review article on n-3 fatty acids 
S86 Wigmore SJ, et al86 1997 No supplements used – not meeting criteria 
S87 Falconer JS87 1994 n-3 supple not used -  not meeting criteria 
S88 Whitehouse AS, et al88 2001 Animal study 
S89 Sauer LA, et al89 2000 Animal study 
S90 Ovesen L, et al90 1993 For literature review 
S92 Ovesen L, et al17 1993 For literature review 
S93 Barber MD, et al91 1998 Abstract 
S94 Barber MD, et al92 1997 Abstract of S71  
S95 Tisdale MJ32 1990 Animal study and > 10 years ago 
S97 Holroyde CP, et al93 1988 Abstract and > 10 years ago 
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Appendix 6.5 Bibliographic information and study identification numbers of the included 
studies 
 
STUDY 
ID 
AUTHOR TITLE JOURNAL YEAR SOURCE 
S3 Fearon KCH, 
et al35 
Effect of a protein and energy 
dense n-3 fatty acid enriched 
oral supplement on loss of 
weight and lean tissue in 
cancer 
Gut 2003 Medline / Ovid / 
Zetoc / Internet 
S6 Bruera E, et 
al41 
Effect of fish oil on appetite 
and other symptoms in 
patients with advanced cancer 
and anorexia/cachexia: A 
double-blind placebo-
controlled study 
J of Clinical 
Oncology 
2003 Medline / 
CINAHL / 
Cochrane / 
Internet  
S10 Barber MD34 Effect of a fish-oil enriched 
nutritional supplement on 
metabolic mediators in patients 
with pancreatic cancer 
cachexia 
Nutrition and 
Cancer 
2001 Medline / 
Embase / 
CINAHL / Zetoc 
/ internet 
S13 Barber MD42 Tolerance and Incorporation of 
a high-dose eicosapentaenoic 
acid diester emulsion by 
patients with pancreatic cancer 
cachexia 
Lipids 2001 Medline / Zetoc 
/ Internet 
S17 Zuijdgeest-
Van Leeuwen 
SD45 
Eicosapentaenoic acid ethyl 
ester supplementation in 
cachectic cancer patients and 
healthy subjects: effects on 
lipolysis and lipid oxidation 
Clinical 
Nutrition 
2000 Medline / 
Embase / Zetoc 
S20 Wigmore SJ43 Effect of oral eicosapentaenoic 
acid on weight loss in patients 
with pancreatic cancer 
Nutrition and 
Cancer 
2000 Medline / Cinahl 
/ Zetoc / 
Internet 
S21 Barber MD46 Metabolic response to feeding 
in weight-losing pancreatic 
cancer patients and its 
modulation by a fish-oil-
enriched nutritional 
supplement 
Clinical 
Science 
2000 Medline / Zetoc 
/ Internet 
S22 Burns PC38 Phase I clinical study of fish oil  
fatty acid capsules for patients 
with cancer cachexia: Cancer 
and Leukemia Group B Study 
9473 
Clinical Cancer 
Research 
1999 Medline / 
Embase / 
Internet 
S23 Barber MD40 The effect of an oral nutritional 
supplement enriched with fish 
oil on weight loss in patients 
with pancreatic cancer 
British Journal 
of Cancer 
1999 Medline / Zetoc 
/ Internet 
S28 Wigmore SJ94 Down-regulation of the acute 
phase response in patients 
with pancreatic cancer 
cachexia receiving oral 
eicosapentaenoic acid is 
mediated via suppression of 
interleukin-6  
Clinical 
Science 
1997 Medline / Zetoc 
S31 Wigmore SJ95 The effect of polyunsaturated 
fatty acids on the progress of 
cachexia in patients with 
pancreatic cancer 
Nutrition 1996 Medline / Zetoc 
/ Internet 
S60 Barber MD96 Fish-oil enriched nutritional 
supplement attenuates 
progression of the acute-phase 
response in weight-losing 
patients with advanced 
pancreatic cancer 
Journal of 
Nutrition 
1999 Zetoc / Internet 
S63 Burns CP39 Phase II study of-dose fish oil 
capsules for patients with 
cancer-related cachexia 
Cancer 2004 Clinicaltrials.gov 
/ Internet 
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STUDY 
ID 
AUTHOR TITLE JOURNAL YEAR SOURCE 
S71 Barber MD97 Eicosapentaenoic acid 
attenuates cachexia 
associated with advanced 
pancreatic cancer 
International 
congress on… 
1997 Zetoc 
S79 Moses AWG19 Reduced total energy 
expenditure and physical 
activity in cachectic patients 
with pancreatic cancer can be 
modulated by an energy and 
protein dense oral supplement 
enriched with n-3 fatty acids 
British Journal 
of Cancer 
2004 Zetoc 
S91 Gogos CA44 Dietary Omega-3 
polyunsaturated fatty acids 
plus vitamin E restore 
immunodeficiency and prolong 
survival for severely ill patients 
with generalized malignancy 
Cancer 1998 Hand searching 
references 
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Appendix 6.6 Study quality assessment tool - guidelines 
 
STUDY QUALITY ASSESSMENT TOOL - GUIDELINES 
 
For each study, the following questions need to be answered: 
1. Was the study described as randomised (this includes the use of words 
such as randomly, random, and randomisation)? 
2. Was the study described as double blind? 
3. Was there a description of withdrawals and dropouts? 
Scoring the answers: 
- 1 point is allocated for each ‘yes’ answer 
- 0 points are allocated for ‘no’ answers 
 Additional points can be allocated as follows: 
 Question 1 
- An additional point can be allocated if the method to generate 
the sequence of randomisation was described and if it was 
appropriate 
Question 2 
- An additional point can be allocated if the method of double 
blinding was described and it was appropriate 
Deduction of points can occur as follows: 
Question 1 
- A point can be deducted if the method of randomisation was 
described but it was inappropriate 
- For example; patients allocated alternately, according to date of 
birth, or hospital number 
Question 2 
- A point can be deducted if the study was described as double 
blind but the method of blinding was inappropriate 
 
1 Guidelines for assessment 
1.Randomisation 
A method to generate the sequence of randomisation will be regarded as 
appropriate if it allowed each study participant to have the same chance of 
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receiving each intervention and the investigators could not predict which 
treatment was next. Methods of allocation using date of birth, date of 
admission, hospital numbers, or alternation should not be regarded as 
appropriate. 
 
2. Double blinding 
A study must be regarded as double blind if the word ‘ double blind’ is used. 
The method will be regarded as appropriate if it is stated that neither the 
person doing the assessments nor the study participant could identify the 
intervention being assessed, or if in the absence of such a statement the use 
of active placebos, identical placebos or dummies is mentioned. 
 
3. Withdrawals and dropouts 
Participants who were included in the study but did not complete the 
observation period or who were not included in the analysis must be 
described. The number and the reasons for withdrawal in each group must be 
stated. If there were no withdrawals, it should be stated in the article. If there 
is no statement on withdrawals, this item must be given no points. 
 
4. Quality assessment 
Once a total score for each study has been calculated, the quality of each 
study can be ascertained. A score of 3 and above will be considered as good 
quality study whereas a score below 3 will be regarded as a poor quality 
study. 
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Appendix 6.7 Study quality assessment tool 
 
STUDY QUALITY ASSESSMENT TOOL 
2 STUDY ID NUMBER____________________ 
REVIEWER__________________ 
 
QUESTION 1: Was the study described as randomised (this includes the use 
of words such as randomly, random, and randomisation)? 
Select answer and specify reason for selection     
          SCORE 
ٱ YES  _________________________________________________ 
ٱ NO  _________________________________________________ 
 
Has the method of randomisation been specified and is it appropriate? 
ٱ YES ________________________________________________ 
ٱ NO ________________________________________________ 
 
Has the method of randomisation been specified and is it INappropriate? 
ٱ YES _______________________________________________ 
ٱ NO ______________________________________________ 
      
  SCORE FOR Q1 __________ 
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QUESTION 2: Was the study described as double blind? 
Select answer and specify reason for selection     
          SCORE 
ٱ YES _______________________________________________ 
ٱ NO _______________________________________________ 
 
Has the method of double blinding been described and is it appropriate? 
ٱ YES _______________________________________________ 
ٱ NO _______________________________________________ 
 
Has the method of double blinding been described and is it INappropriate? 
ٱ YES _______________________________________________ 
ٱ NO _______________________________________________ 
       SCORE FOR Q2 __________ 
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QUESTION 3: Was there a description of withdrawals and dropouts? 
ٱ YES _______________________________________________ 
ٱ NO _______________________________________________ 
       SCORE FOR Q3 __________ 
 
  TOTAL SCORE ________________ 
  STUDY QUALITY ________________ 
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Appendix 6.8 – The results of the study quality assessment of the included studies 
 
Study 
ID 
Question 1 
score 
Question 2 
score 
Question 3 
score 
TOTAL SCORE QUALITY 
S3 2 2 1 5 GOOD 
S6 2 2 1 5 GOOD 
S10 0 0 1 1 POOR 
S13 0 0 1 1 POOR 
S17 1 1 1 3 GOOD 
S20 0 0 1 1 POOR 
S21 0 0 0 0 POOR 
S22 0 0 1 1 POOR 
S23 0 0 0 0 POOR 
S28 0 0 0 0 POOR 
S31 0 0 0 0 POOR 
S60 0 0 0 0 POOR 
S63 0 0 1 1 POOR 
S71 0 0 1 1 POOR 
S79 2 2 0 4 GOOD 
S91 1 0 0 1 POOR 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Stellenbosch University http://scholar.sun.ac.za
 93
Appendix number 6.9.1 –Data extraction: Characteristics of included trials 
 
(*) represents the number of patients remaining at the end of the trial 
ID POPULATION INTERVENTION OUTCOME MEASURES USED DROP-OUT (%) TRIAL PERIOD 
(wks) 
 SIZE 
(n=#)(*) 
TYPE n-3 SUPPLE 
(n=#)(*) 
n-3 ENRICHED NUTR  
SUPPLE (n=#)(*) 
PLACEBO 
(n=#)(*) 
   
S3 200(110) Pancreas  95(50) 105 (60) Weight 
Body composition 
Dietary Intake 
Quality of life 
15 (b/line) – 7.5% 
8C ; 7E 
52 (4wks) – 26% 
27C ; 25E 
90 (8wks) – 45% 
45C ; 45E 
8 weeks 
S6 91(60) Mixed 46 (30)  45 (30) Appetite , Nausea 
Tiredness 
dietary intake 
 weight 
Body composition 
functional status 
16 – 35% 2 weeks 
S10 20(18) pancreas  20 (18) No controls Hormone and metabolic indicators 
weight 
2 – 10% 3 weeks 
S13 5(5) pancreas 5 (5)  No controls Weight 
Performance status 
Adverse effects 
0% 8 weeks 
S17 17 (7) Mixed 9 (3)  8 (4) Lipolysis 
Lipid oxidation 
Weight 
Dietary intake 
10 (59%) 
4C ; 6E 
12 weeks 
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ID POPULATION INTERVENTION OUTCOME MEASURES USED DROP-OUT (%) TRIAL PERIOD 
(wks) 
 SIZE 
(n=#)(*) 
TYPE n-3 
SUPPLE 
(n=#)(*) 
n-3 ENRICHED NUTR  
SUPPLE (n=#)(*) 
PLACEBO (n=#)(*)    
S20 26 (14) Pancreas 26 (14)  No controls Anthropometry 
Body composition 
Performance status 
Toxicity , Dietary intake 
5 – 4 wks (19%) 
10 – 8wks (38%) 
12 – 12 wks (46%) 
12 weeks 
 S21 16 Pancreas  16 6 (baseline study) Weight 
Body composition 
Energy expenditure 
Dietary intake 
Not reported 3 weeks 
S22 25 (22) Mixed 25(22)  No controls Weight 
Toxicity 
3 – (12%) 8 weeks  
S23 
 
 
20 (13) Pancreas  20 (13)  Anthropometry 
Body Composition 
Nutritional Intake , Appetite 
Energy Expenditure 
Acute Phase Response 
Performance Status 
2 – 3wks (10%) 
7 – 7wks (35%) 
7 weeks 
S28 6 Pancreas 6   APR Not reported 4 weeks 
S31 18 Pancreas 18   Weight 
Body composition 
Energy expenditure 
Acute phase response 
0 3 months 
(*) represents the number of patients remaining at the end of the trial 
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ID POPULATION INTERVENTION OUTCOME MEASURES USED DROP-OUT (%) TRIAL PERIOD 
(wks) 
 SIZE 
(n=#)(*) 
TYPE n-3 SUPPLE  
(n=#)(*) 
n-3 ENRICHED 
NUTR  SUPPLE 
(n=#)(*) 
PLACEBO (n=#)(*)    
S60 36 Pancreas N/A 18 18 – supportive care Acute phase proteins 
Weight 
Not reported Not reported 
S63 43 (10) Mixed  43 (10)   Weight 
Quality of life 
33 (76%) 1.2 months 
(median) 
0.5 days – 3.1 
months 
S71 27 (9) pancreas 27 (9)   Weight 
APR 
Energy expenditure 
5 – 0 wks 
(18%) 
0 – 4 wks 
(0%) 
9 – 8 wks 
(33%) 
11 – 12 wks 
(40%) 
18 – 24 weeks 
(66%) 
24 weeks 
S79 24 Pancreas  9(7) 15(12) Energy expenditure 
Weight 
Dietary Intake 
Body Composition 
5 – 8 wks (21%) 8 weeks 
S91 60 Mixed 30  30 Weight 
Cytokine production 
Performance Status 
4 (6.25%) 40 days 
        (*) represents the number of patients remaining at the end of the trial 
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         Appendix number 6.9.2.1 –Data extraction: Summarising the evidence – Population characteristics of the Treated group  
 
TREATED PATIENTS STUDY 
ID Size before Size after M:F Supple Tumour Site Age (yrs) % wt loss 
(prior to trial) 
Period of wt loss 
(mo) 
S3 95 50 54:41 ENS pancreas 67 17.9 6 
S6 46 30 10:20 capsules 7 GU 
2 Breast 
2 unknown 
11 GI 
6 Lung 
1 h&n 
1 sarcoma 
63±9.1 16.0±11  
S10 20 18 10:10 ENS Pancreas 62 17.9 2 
S13 5 5 2 capsules pancreas 2 2 2 
S17 9 3 8:1 capsules 4 GI 
1 pancreas 
1 rectal 
1 renal 
1 breast 
1 lung 
64 13±4 6 
S21 16 2 10:6 
 
ENS Pancreas 63 17.7 2 
S23 20 13 10:10 ENS Pancreas 62 17.9 2 
S28 6 2 5:1 Capsule pancreas 58±5 12.7±3.2 7.3±1.7 
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TREATED PATIENTS STUDY ID 
Size before Size after M:F Supple Tumour Age (yrs) % wt loss Period of wt loss 
(mo) 
S31 18 18 2 capsules pancreas 2 2 2 
S20 26 14 12:14 capsules pancreas 56 13 4 
S22 25 22 12:10 capsules 4 pancreas 
9 lung 
2 cervical 
1 sarcoma 
1 rectal 
1 breast 
1 hepatocellular 
1 renal 
1 CLL 
1 neuroendocrine 
64 2 2 
S60 18 2 2 ENS Pancreas 64 17.9 2 
S71 27 9 13:14 capsules pancreas 58 14 4 mo 
S79 9 7 6:3 ENS pancreas 65 21 6 mo 
S91 30 2 17:13 Capsule 6 breast 
10 GI 
5 lung 
4 liver 
5 pancreas 
58±4 6.7±0.8 – 
13.3 ± 0.7 
2 
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TREATED PATIENTS STUDY ID 
Size before Size after M:F Supple Tumour Agyrs) % wt loss Period of wt loss 
(mo) 
S63 43 10 29:14 capsules 8 colorectal 
9 lung 
8 unknown 
2 sarcoma 
2 breast 
2 gastric 
2 renal 
2 neuroendocrine 
2 myelodysplastic 
1 pancreas 
1 anal 
1 CLL 
1 h&n 
1 hepatic 
1 myeloma 
67 2.7 1 
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             Appendix number 6.9.2.2 – Data extraction: Summarising the evidence – Population characteristics of the Control group 
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONTROL PATIENTS STUDY ID 
Size before Size After M:F age % wt loss Tumour 
S3 105 60 56:49 68 17.1 Pancreas 
 
S6 45 30 7:23 64.6±9.4 15.6±8 4 GU 
4 breast 
4 unknown 
10 GI 
5 lung 
1 haematologic 
2 sarcoma 
S10 - - - - - - 
 
S13 - - - - - - 
 
S17 8 4 5:3 64±5 10±5 1 oeso 
1 pancreas 
1 breast 
1 cervical 
1 carcinoid 
1 unknown 
1 lung 
1 mesothelioma 
S20 - - - - - - 
 
S21 6 Baseline study only 3:3 54 0 none 
 
S22 - - - - - - 
 
S23 - - - - - - 
 
S28 - - - - - - 
 
S31 - - -   - 
 
S60 18 2 2 60 11.8 pancreas 
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S63 - - - - - - 
 
S71 - - - - - - 
 
S79 15 12 4:11 70 19 pancreas 
 
S91 30 2 19:11 57±4 5.8±0.7 – 14.6±2.1 7 breast 
11 GI 
6 lung 
3 liver 
3 pancreas 
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            Appendix number 6.9.3 – Details of the type and dose of EPA supplements used 
 
STUDY ID TYPE OF n-3 SUPPLEMENT USED RECOMMENDED INTAKE PER DAY 
(grams EPA / d) 
ACTUAL INTAKE PER DAY 
(grams EPA/ d) 
S3 ENS 2 x 237ml of supplement / d –  (2.2g  EPA) 1.4 x 237ml / d  - (1.54g EPA) 
(70% of recommendation) 
S6 Capsules 18 x 1000mg capsules – (3.24g EPA)  Mean of 9.8 capsules per day (1.76g EPA) 
(54% of recommendation) 
S10 ENS 2 x 237ml cans – (2.2g EPA) 1.25 – 2.0 cans per day, median – 1.9 cans per day 
(1.4 – 2.2g EPA ; median 2.1g EPA) 
(62.5 – 100% of recommendation – 95% median) 
S13 95% EPA diester liquid emulsion Dose escalation study 
25ml emulsion/d (4.5g EPA) – 200ml emulsion 
(36g EPA) 
Dose increased over 8 weeks and then maintained 
2 pts = 100ml/d (18g EPA) 
1 pt = 150ml / (27g EPA) 
2pts = 200ml/d (36g  EPA) – 1 week only then reduced dose 
S17 EPA 95EE 6g of EPA capsules  >90% compliance ~ > 5.4g EPA capsules 
S20 >95% EPA  capsules 1g/ d – week1 
2g / d – week 2 
4g/ d – week 3 
6g/d – weeks 4 - 12 
Not reported 
S21 ENS 2 x 237ml cans – (2.2g EPA) 1.25 – 2.0 cans per day, median – 1.9 cans per day 
(1.4 – 2.2g EPA ; median 2.1g EPA) 
(62.5 – 100% of recommendation – 95% median) 
S22 Capsules 0.1g/kg/d  to start and escalated at 2 week 
intervals if tolerated 
0.3g / kg / d was the MTD 
0.113g EPA / kg / day 
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STUDY ID TYPE OF n-3 
SUPPLEMENT 
USED 
RECOMMENDED INTAKE PER DAY 
(grams EPA / d) 
ACTUAL INTAKE PER DAY 
(grams EPA / d) 
S23 ENS 2 x237 ml cans – (2.2g EPA) 1.2 – 2.0 cans per day, median – 1.9 cans per day 
1.3 – 2.0g EPA, median 2.1g EPA  
S28 >95% EPA  capsules 1g/ d – week1 
2g / d – week 2 
4g/ d – week 3 
6g/d – weeks 4 - 12 
1g/ d – week1 
2g / d – week 2 
4g/ d – week 3 
6g/d – weeks 4 - 12 
S31 Capsules (MaxEPA) 2 – 16g fish oil (0.34 – 2.72g EPA) 
Dose escalated over 12 weeks 
12g fish oil / day (2g EPA/d) 
S60 ENS 2 x 240ml cans – (2.18g EPA) Not reported 
S63 Capsules 0.15g / kg – (0.067g EPA / kg) 0.15 – 0.2g / kg (0.067 – 0.086g EPA / kg / d) 
S71 Capsules 1g/ d – week1 
2g / d – week 2 
4g/ d – week 3 
6g/d – weeks 4  
Maintenance dose – 6g/d EPA 
All did dose escalation 
5 x continued: 12 – 16g/d  (2.2 – 2.9g EPA / d) 
22 x continued: 12g / d (6g EPA / d) 
 
 
S79 ENS 2 x 237mlcans / d (2.2g EPA)  1.9 x 237ml /d 
S91 Capsules 18g fish oil / d (18 x 170mg EPA) Not reported 
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             Appendix 6.9.4 – Weight change 
 
WEIGHT (kg) WEIGHT CHANGE 
(Median – kg) 
COMMENT / EFFECT STUDY 
ID 
INTERVENTION 
BEFORE DURING AFTER Median kg  
 Experimental 
(E) 
Control (C) E C E C E C   
S3 ENS NS 60.3 61.4 60.05 61.03 59.8 60.66 E: -0.25 kg / mo 
C: -0.37 kg / mo 
p= 0.74 Not significant 
Compared to the rates of weight 
loss at baseline – significant 
attenuation of wt loss at 4 & 8 
wks (p< 0.001) 
S10 ENS -  - - -  - Median wt gain of 1kg Only change in weight reported 
S21 ENS - 55.2 - - - 56.2 - Median wt gain of 1kg 
– 3wks 
p = < 0.05 
significant 
S23 ENS - 55.2 - 56.2 - 57.2 - +1.0 – 3wks 
+2.0 – 7 wks 
p = 0.024 
p = 0.033 
significant 
S60 ENS Supportive 
care 
55.0 58.5     E: ↑ 1kg / 4 wk 
C: ↓ 2.8 kg / 4 wk 
Significant 
More details requested but not 
received 
S79 ENS -       0.0 Not significant 
Details requested but not 
received 
S28 Capsules -        NOT MEASURED 
S13 Emulsion -        Not reported 
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WEIGHT (kg) WEIGHT CHANGE 
(Median – kg) 
COMMENT / EFFECT STUDY 
ID 
INTERVENTION 
BEFORE DURING AFTER Median kg  
 Experimental 
(E) 
Control 
(C) 
E C E C E C   
S6 Capsules Olive oil 60.8 61.1 - - 60.83 60.21 E: 0.03 ± 2.8 
C: -0.89 ± 3.8 
Not significant 
S17 Capsules Oleic 
acid 
capsules 
67 
± 10 
63 
± 10 
    Not measured due to high drop –out rate by end of trial, 
therefore unable to draw any conclusions 
S20 Capsules - 66.8 
 
- 66.0 –  
4wks 
65.2 – 
8wks 
- 65 - 0: -2.0 kg / mo 
4: +0.5 kg  / mo 
8: +0.2 kg  / mo 
12: +0.3 kg  / mo 
p < 0.0005 
significant 
S22 Capsules - 62 - - - Not 
specifie
d 
- Not specified Weight change was significantly 
associated with time on 
treatment. 
P = 0.028 
S31 Capsules - 62 - 63 - 62 - 0.3 kg / mo Not significant 
S63 Capsules - 64 -    - ↓ 0.8 kg  Significance not stated 
S71 Capsules - 68.8 - 66.0 – 
4wks 
65.2 – 
8wks 
- 64.5 – 
12wks 
62.2 – 
24wks 
- 0: -2.2 kg / mo 
4: +0.75 kg / mo 
8: +0.2 kg / mo 
12: +0.3 kg / mo 
24: +0.1 kg / mo 
Significant rate of weight loss at 
4wks, no significant change 
thereafter. 
Change in median body weight 
not significant either 
S91 Capsules Placebo       No change in body 
weight 
More details requested but not 
received 
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  Appendix 6.9.5.1 – Body composition - lean body mass 
BODY COMPOSITON (LBM –KG) STUDY 
ID 
INTERVENTION 
BEFORE DURING AFTER 
CHANGE IN LBM      
(kg) 
COMMENT / EFFECT 
 Experimental 
(E) 
Control 
(C) 
E C E C E C   
S6 Capsule Olive oil 24 23.7 - - 24.49 23.15 E: +0.49 ± 6.2 kg 
C: -0.55 ± 3.9 kg 
Not significant 
S3  ENS NS 43.3 43.4 43.57 43.52 43.84 43.64 E: +0.27 kg / mo 
C: +0.12 kg / mo 
p = 0.88 
not significant 
S21 ENS -       median 0.75kg 
(+ 0.1 – 1.6kg)  
Significant p < 0.05 
Only change in LBM reported 
S23 ENS - 41.5 N/A 42.5 N/A 43.4 N/A 3 wk: +1.0 (0.6 ±1.4)  
7 wk: +1.9 (1.0 ± 3.0) 
p = 0.0064 
p = 0.0047 
Significant changes 
S79 ENS NS       E: 0.3 kg    C: 0.6 kg NOT REPORTED 
S10  ENS         NOT MEASURED 
S13 emulsion         NOT MEASURED 
S17 Capsules Oleic 
acid 
       NOT MEASURED 
S20 Capsules -        NOT MEASURED 
S22 Capsules -        NOT MEASURED 
S28 Capsules -        NOT MEASURED 
S31 Capsules -        NOT MEASURED 
S60 Capsules Supp 
care 
       NOT MEASURED 
S63 Capsules -        NOT MEASURED 
S71 Capsules -        NOT MEASURED 
S91 Capsules Placebo        NOT MEASURED 
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Appendix 6.9.5.2 – Body composition - Fat mass 
 
BODY COMPOSITON (FM – % / kg) STUDY ID INTERVENTION 
BEFORE DURING AFTER 
CHANGE IN FM 
(kg) 
COMMENT / EFFECT 
 Experimen
tal (E) 
Control (C) E C E C E C   
S21 ENS - 28.1% -   28.1% - Unchanged 
0.0 kg 
Not significant 
S23 ENS - 14.5 kg - 14.3 kg - 14.7 kg  3 wk: -0.2 (-0.8 ± 0.9)  
7 wk: +0.2 (-0.8 ± 2)  
Not significant 
S6 Capsule Olive oil       Measured but no details reported 
S10 ENS -        NOT MEASURED 
S60 ENS Supp care        NOT MEASURED 
S3 ENS NS        NOT MEASURED 
S79 ENS NS        NOT MEASURED 
S13 emulsion -        NOT MEASURED 
S17 Capsules Oleic acid        NOT MEASURED 
S20 Capsules -        NOT MEASURED 
S22 Capsules -        NOT MEASURED 
S28 Capsules -        NOT MEASURED 
S31 Capsules -        NOT MEASURED 
S63 Capsules -        NOT MEASURED 
S71 Capsules -        NOT MEASURED 
S91 Capsules Placebo        NOT MEASURED 
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Appendix 6.9.5.3 – Body composition - % body water 
 
BODY COMPOSITON (% body water) STUDY 
ID 
INTERVENTION 
BEFORE DURING AFTER 
CHANGE IN   % BODY 
WATER 
COMMENT / EFFECT 
 Experimental 
(E) 
Control 
(C) 
E C E C E C   
S20 Capsules - 50.9 - 49.5(4) 
49.3(8) 
- 49.1(12) - -1.8% Not significant 
S31 Capsules - 56 - 55 - 55 - 0 / 1mo / 3mo  Not significant 
S23 ENS - 52.9 - 53.0 - 52.8 - 3wk:+0.1 (-0.3 ± 1.9) 
7wk: -0.1 (-0.4 ± 1.5) 
Not significant 
S6 Capsules Olive oil       Measured but no details reported 
S3 ENS NS        NOT MEASURED 
S10 ENS -        NOT MEASURED 
S21 ENS -        NOT MEASURED 
S60 ENS Supp care        NOT MEASURED 
S79 ENS NS        NOT MEASURED 
S13 emulsion -        NOT MEASURED 
S17 Capsules Oleic acid        NOT MEASURED 
S22 Capsules -        NOT MEASURED 
S28 Capsules -        NOT MEASURED 
S63 Capsules -        NOT MEASURED 
S71 Capsules -        NOT MEASURED 
S91 Capsules Placebo        NOT MEASURED 
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Appendix 6.9.6 – Energy expenditure 
2.1.1 REE ( kcal/d / kcal / kg /d) STUDY 
ID 
ASSESSMENT 
TOOL USED 
INTERVENTION 
BEFORE DURING AFTER 
COMMENT / EFFECT 
  Experimental 
(E) 
Control (C) E C E C E C  
S21 Indirect Calorimetry ENS - 1354 /  
23.9 
-   1295 / 
23.5 
- p > 0.1 
Significant p<0.05 
S23 Indirect Calorimetry ENS - 1339 / 
24.2 
- 1303 / 
24 
-   p = 0.18 Significant 
p = 0.025 
S79 Indirect Calorimetry ENS NS 1387    1386  - 1 kcal / d 
p< 0.05 
S17 Indirect Calorimetry Capsules Oleic acid -  / 
22.3 
-  /  
23.4 
-  /  
22.5 
- /  
23.8 
  NO CHANGE 
S31 Indirect Calorimetry Capsules  -  /  
25 
- - /  
24 
-  - /  
26 
- 0 / 1 / 3 mo 
Not significant 
S71 Indirect Calorimetry Capsules - 1815 /  
23.4 
- 1570 / 
22.8 
    p = 0.17 0 / 1 mo 
Not significant p= 0.15 
S3   ENS NS       NOT MEASURED 
S10   ENS -       NOT MEASURED 
S60  ENS Supp Care       NOT MEASURED 
S6  Capsules Olive oil       NOT MEASURED 
S13  Emulsion -       NOT MEASURED 
S20  Capsules -       NOT MEASURED 
S22  Capsules -       NOT MEASURED 
S28  Capsules        NOT MEASURED 
S63  Capsules -       NOT MEASURED 
S91  Capsules Placebo       NOT MEASURED 
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Appendix 6.9.7.1 - Dietary intake  - energy intake 
DIETARY INTAKE (kcal / day) STUDY 
ID 
ASSESS 
TOOL USED 
INTERVENTION 
BEFORE DURING AFTER 
CHANGE 
IN 
INTAKE 
(kcal/d) 
COMMENT / EFFECT 
  Experimental 
(E) 
Control 
(C) 
E C E C E C   
S3 3 day food 
diaries 
ENS NS 1504 
 
1613 - - 1281 1237 E: -223 
C:-376 
p ≤ 0.001 
p ≤ 0.001 
S23 3 day food 
diary 
ENS  1450 - 1798 
(3 wks) 
- - - +372 
(median) 
p = 0.0016 
Significant increase 
S79 3 day diet 
dairy 
ENS NS 1574 1814 - - 2048 1980 474 p < 0.05 
S6 3 day food 
records 
Capsules Olive oil 1386 
 
1349 
 
- - - - E: 51 
C:-57 
Not significant 
Not significant 
S17 Diet records  Capsules Oleic acid 1964 
± 634 
1459 
± 485 
- - 2098.6 
± 765 
1546.2 
± 374 
E: 134.6 
C: 87.2 
7 Day period 
S20 Not specified Capsules - 1777 - 1828 - - - +51  
S21 3 day food 
diary 
ENS         Details not reported 
S10  ENS -        NOT MEASURED 
S60  ENS Supp care        NOT MEASURED 
S13  Emulsion -        NOT MEASURED 
S22  Capsules -        NOT MEASURED 
S28  Capsules -        NOT MEASURED 
S31  Capsules -        NOT MEASURED 
S63  Capsules         NOT MEASURED 
S71  Capsules         NOT MEASURED 
S91  Capsules Placebo        NOT MEASURED 
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Appendix 6.9.7.2 – Dietary intake - protein intake 
DIETARY INTAKE (g/day) STUDY 
ID 
ASSESS 
TOOL USED 
INTERVENTION 
BEFORE DURING AFTER 
CHANGE IN 
INTAKE (g/d) 
COMMENT / 
EFFECT 
  Experimental 
(E) 
Control 
(C) 
E C E C E C   
S3 3 day food 
diaries 
ENS NS 60 63 - - 52 46 E: -8 
C:-17 
p ≤ 0.05 
p ≤ 0.001 
S79 3 day diet 
diary 
ENS NS 57 73 - - 84 77 27 p < 0.05 
S6 Visual analog 
scale 
3 day food 
records 
Capsules Olive oil        NOT MEASURED 
Details not  
available 
S10   ENS -        NOT MEASURED 
S21 3 day food 
diary 
 ENS -        NOT REPORTED 
S23 3 day food 
diary 
ENS -  -  - - -  NOT MEASURED 
S60  ENS Supp care        NOT MEASURED 
S13  Emulsion -        NOT MEASURED 
S17 Diet records  Capsules Oleic acid        NOT MEASURED 
S20  Capsules -  -  - - -  NOT MEASURED 
S22  Capsules -        NOT MEASURED 
S28  Capsules -        NOT MEASURED 
S31  Capsules -        NOT MEASURED 
S63  capsules -        NOT MEASURED 
S71  Capsules -        NOT MEASURED 
S91  Capsules Placebo        NOT MEASURED 
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Appendix 6.9.8 – Appetite 
APPETITE STUDY 
ID 
ASSESS 
TOOL USED 
INTERVENTION 
BEFORE DURING AFTER 
CHANGE IN 
APPETITE 
(median) 
COMMENT / EFFECT 
  Experimental 
(E) 
Control 
(C) 
E C E C E C   
S6 VAS Capsules Olive oil 57.5 66.5     E:-9.8 
C:-9.0 
Not significant 
Details not reported 
S23 Numerical 
rating scale 
ENS - 5 - 6 (3wk) - 6 
(7wk) 
-  3wk: p = 0.001 significant 
7wk:  not significant 
S3  ENS NS        NOT MEASURED 
S10  ENS -        NOT MEASURED 
S13  Emulsion -        NOT MEASURED 
S17  capsules Oleic acid        NOT MEASURED 
S20  capsules -        NOT MEASURED 
S21  ENS -        NOT MEASURED 
S22  Capsules -        NOT MEASURED 
S28  Capsules -        NOT MEASURED 
S31  Capsules -        NOT MEASURED 
S60  ENS Supp care        NOT MEASURED 
S63  Capsules -        NOT MEASURED 
S71  Capsules -        NOT MEASURED 
S79  ENS NS        NOT MEASURED 
S91  Capsules Placebo        NOT MEASURED 
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Appendix 6.9.9 – Functional status 
FUNCTIONAL STATUS SCORE CHANGE COMMENT / EFFECT ID ASSESSMENT 
TOOL USED 
INTERVENTION 
BEFORE DURING AFTER   
  Experimental 
(E) 
Control 
(C) 
E C E C E C   
S3 Karnofsky (0-100) ENS NS 74.9 73.9      Not significant – 4 & 8 wks not reported 
S79 Physical Activity 
Level  
(PAL =TEE/REE) 
ENS        E: 0.18 
C: 0.01 
Only change reported 
S23 Karnofsky (0-100) ENS - 85 - 95 - 95 - 3wks: +10 
7wks: +10 
p = 0.0047 
p = 0.046 
S6 Karnofsky (0-100) 
EFAT (0-30) 
Capsules Olive oil 69.7 
4.9 
63.3 
5.8 
- 
- 
- 
- 
69.7 
5.2 
56.4 
6.0 
E:0.0 ;C:-6.9 
E: 0.2 ; C:0.3 
Change not significant 
Change not significant 
S13 Karnofsky (0-100)  Emulsion -        NOT REPORTED 
S20 WHO Performance 
status 
Capsules - 1 - 
 
1(4wk) 
1(8wk) 
- 0 -  Not significant 
S63 FAACT 
FACT-G 
Capsules -       3.3 (-140 – 18.2) 
1.9 (-7.8 – 13.5) 
Only change reported 
S91 Karnofsky (0-100) Capsules Placebo 77 / 51 72 / 54   - / 72 - / - NOT 
REPORTED 
Well nourished / malnourished 
Significant increase in malnourished 
group  
S10  ENS -        NOT MEASURED 
S21  ENS -        NOT MEASURED 
S60   ENS Supp care        NOT MEASURED 
S17  Capsules Oleic acid        NOT MEASURED 
S22  Capsules -        NOT MEASURED 
S28  Capsules -        NOT MEASURED 
S31  Capsules -        NOT MEASURED 
S71  Capsules -        NOT MEASURED 
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Appendix 6.9.10 – Acute phase response 
CRP (mg /L) ID MEASUREMENT INTERVENTION 
BEFORE DURING AFTER 
COMMENT / EFFECT 
  Experimental 
(E) 
Control (C) E C E C E C  
S23 Serum CRP ENS - 10 - 10(3wk) - 10(7wk) - No change / Not significant 
S60 Serum CRP ENS Supportive 
care 
<5 11     Only baseline data reported 
S17 Serum CRP Capsules Oleic acid 37 37 - - 41 31 Not significant 
S20 Serum CRP Capsules -       Not specified – only no. with 
increased CRP levels stated 
S28 Serum CRP Capsules - 11.0 -  - 0.8(4wk)  Significant change 
S31 Serum CRP Capsules - 15 - 10(4wk) - 16(12wk) - 4 wk: p < 0.002 
12 wk: not significant 
S71 Serum CRP Capsules -       B/Line: 36% ↑  
4wk:25%↑ CRP (p> 0.05)  
12wk: 37% ↑ CRP 
Changes in CRP levels were 
significantly negatively 
correlated with changes in 
weight 
(r= -0.28, p< 0.04) 
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CRP (mg /L) ID MEASUREMENT INTERVENTION 
BEFORE DURING AFTER 
COMMENT / EFFECT 
  Experimental 
(E) 
Control (C) E C E C E C  
S3   ENS NS       NOT MEASURED 
S79  ENS NS       NOT MEASURED 
S10  ENS -       Although ARP measured, no 
CRP 
S21  ENS -       NOT MEASURED 
S13  emulsion -       NOT MEASURED 
S6  Capsules Olive oil       NOT MEASURED 
S22  Capsules -       NOT MEASURED 
S63  Capsules -       NOT MEASURED 
S91  Capsules Placebo       CRP NOT MEASURED 
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Appendix 6.9.11 – Adverse effects and quality of life 
QUALITY OF LIFE SCORE STUDY 
ID 
ASSESSMENT TOOL 
USED 
INTERVENTION 
BEFORE AFTER 
ADVERSE EFFECTS EFFECT 
  Experimental 
(E) 
Control (C) E C E C   
S3 EuroQol EQ – 5D index 
Eurocol EQ – 5D vas 
EORTC – QLQ-C30 
EORTC – QLQ – C30 
ENS NS     None reported Q of L NOT reported 
S6  Capsules      Belching x 2 
Nausea x2 
Vomiting x 1 
Constipation x 1 
Q of L NOT MEASURED 
S13  Capsules      Sensation of fullness x3 
Steathorrea x2 
Nausea x 1 
Abdominal pain x 2 
Q of L NOT MEASURED 
S20  Capsules -     Nausea x3 
Steatthorea x2 
Taste 
Others – not specified 
Q of L NOT MEASURED 
S22  Capsules -     Taste x 10 
Body smell x 6 
Belching x 15 
Flatulence x 9 
Nausea x 2 
Diarrhoea 
Q of L NOT MEASURED 
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QUALITY OF LIFE SCORE STUDY 
ID 
ASSESSMENT TOOL 
USED 
INTERVENTION 
BEFORE AFTER 
ADVERSE EFFECTS EFFECT 
  Experimental 
(E) 
Control (C) E C E C   
S23  ENS -     Steatthorea x 3 Q of L NOT MEASURED 
S31  Capsules -     Taste 
Diarrhoea 
Q of L NOT MEASURED 
S63 FAACT Capsules      Nausea x11 
Taste x19 
Belching x9 
Flatulence x9 
Emesis x8 
Diarrhoea x7 
Body smell x4 
Dyspepsia x2 
Q of life not reported 
S60  ENS      Not reported Q of L NOT MEASURED 
S10  ENS      NOT  REPORTED Q of L NOT MEASURED 
S21  ENS      NOT  REPORTED Q of L NOT MEASURED 
S79  ENS      NOT  REPORTED Q of L NOT MEASURED 
S28  Capsules -     NOT  REPORTED  
S71  Capsules      NOT REPORTED Q of L NOT MEASURED 
S91  Capsules      NOT REPORTED Q of L NOT MEASURED 
S17  Capsules      NOT REPORTED NOT MEASURED 
 
 
 
 
